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Abstract
The arteriovenous fistula (AVF) is a lifeline for patients requiring renal replacement ther-
apy, allowing repeated access to the high blood flow needed for haemodialysis. However,
failure rates for AVFs remain high, at around 30-40 % after one-year, typically occluding
secondary to stenosis. Many risk-factors for AVF failure have been identified, such as
diabetes, age, gender and pre-operative vessel diameters. In this work, existing and po-
tential risk-factors are investigated in a local cohort, with the ultimate aim of identifying
new risk-factors for AVF failure, and opening new pathways for risk-factor identification
in the future.
Three main avenues were followed: The first approach involved using health infor-
matics, electronic records and data linkage to create an accurate picture of a patients AVF
timeline. This retrospective single centre study assessed known risk-factors such as age
and diabetes, and various serological markers such as albumin, c-reactive protein, ferritin
and phosphate in 137 patients. AVF patency rates were also examined in this cohort. De-
creased pre-operative levels of ferritin and increased phosphate were markers of interest
due to association with AVF failure at 1-year. Known risk-factors such as gender and age
showed no effect on AVF outcome in this cohort. Primary patency was observed to be 67
% at one-year, in line with literature values, and primary assisted patency 91 %.
The second approach assessed if modern ultrasound markers of arterial elasticity
(shear wave elastography) and strain (velocity vector imaging) were feasible methods
of assessing arterial stiffness in the peripheral vasculature in a group of 40 volunteers and
47 patients. The methods were then assessed to determine if they could act as risk-factors
for AVF failure in 33 patients who underwent AVF creation. Both methods were feasible
for the assessment of the peripheral vasculature, showing good repeatability, homogene-
ity, and were straight-forward to implement. Using shear wave elastography an increase
in brachial artery elasticity following AVF creation was observed. None of the markers
studied could be proven to act as risk-factors for AVF failure.
xx
The third approach aimed to determine if 3T MRI sequences was a feasible modality
for the pre-operative workup and followup of these patients in a prospective study of 6
patients and 10 healthy volunteers, using three different sequences. 3T MRI was found to
agree with measurements from ultrasound, and also provided the benefit of 3D depiction
of the vessels and high resolution. Finally, using these same MRI images, it was demon-
strated that computational fluid dynamics simulations do not produce equal results if one
changes the MRI sequence used for geometry acquisition.
The difficulty in identifying reliable risk-factors suggests that a multi-factorial ap-
proach may be beneficial. Studies with larger cohorts, and longer followup which com-
bine serological markers, comorbidities, and results from imaging may be needed to iden-
tify risk-factors which finally increase patency rates.
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Chapter 1
Introduction
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1.1 The Kidneys and Kidney Disease
1.1.1 The Kidneys
The kidneys are vital organs, supporting life through the filtration of waste products from
the blood. They are two bean-shaped major organs which lie in the posterior abdominal
region (see figure 1.1), and are surrounded by a layer of perinephric fat. The main function
of the kidney is to process the blood, filtering and reabsorbing different chemicals and
proteins. In this process, the kidneys produce urine for excretion, which is transported
to the bladder through tubes called the ureters. The functional component of the kidney
is the nephron, where the exchange of filtrates occurs. Kidneys also have a role in water
regulation of the body, blood pressure regulation, and hormone excretion.
Decrease in kidney function is a natural consequence of aging, and in old age reports
suggest that the rate of decline is 0.75-1 ml/min/1.73m2 per year. Other factors such
as blood-pressure, injury or diabetes can cause a decline in kidney function. If kidney
function declines to an unsustainable level, some form of renal replacement therapy (RRT)
is required in order to sustain a patients life.
Figure 1.1: The kidneys are two bean-shaped major organs, producing urine which is then transported to
the bladder for excretion. (National Institute of Diabetes and Digestives and Kidney Disease)
3
1.1.2 Chronic Kidney Disease and End-Stage Renal Disease
Chronic kidney disease (CKD), describes a spectrum of conditions which reduce the func-
tion of the kidneys. CKD is commonly defined by a decrease in glomerular filtration rate,
increased albumin excretion, or both. Severe CKD is a significant cause of death, and a
significant reduction in healthy life expectancy. Kidney function can decline to a point
where recovery is unlikely, leading to end-stage renal disease (ESRD), which is the final
stage of CKD when the kidney function has dropped to a level incompatible with life.
Uremic syndrome is the clinical manifestation of kidney failure, and results in an
increased concentration of urea in the blood. Implications include reduced endothelial
function; fluid overload and ureaemia can cause impaired maximal oxygen consumption
resulting in shortness of breath. Decrease in body mass from muscle atrophy, retention of
salt and phosphates, anaemia, and a reduction in the production of hormones are common,
amongst other complications.
When a patient progresses to ESRD, it is necessary to have RRT available to replace
or replicate the function of the kidneys. CKD can be insidious, with earlier stages having
little effect on a patient’s life, and can be asymptomatic.
1.1.3 Prevalence
Prevalence of CKD is estimated to be around 8-16% globally, however this is likely an
underestimation due to treatment gaps in poorer countries [97]. In the US, approximately
12 % of people are estimated to have some form of CKD. Very few patients with CKD
progress to the stage that they develop ESRD and require RRT.
The Scottish Public Health Observatory indicates that there are 179,850 patients with
CKD stage 3-5 in Scotland, giving an estimated prevalence of 3.2 per 100 persons. A
local study conducted in Grampian estimates an 4.7 times higher mortality rate in patients
with CKD compared to the general population [102].
Reports from the Scottish Renal Registry (SRR) state that as of 2016, 5026 individuals
were receiving RRT in Scotland [165] with 573 patients commencing RRT, at an incidence
rate of 10.6 per 100000 persons. The median age of these patients was 61 years. One-year
survival for patients of all age in Scotland receiving RRT was 79 %, falling to 67 % at
2-years and 43 % at 5-years.
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1.1.4 Diagnosis
Diagnostic tests for CKD include blood tests, urine tests, imaging and biopsy. Blood tests
assess levels of waste products in the blood, which may be indicative of inadequate filtra-
tion from the kidneys. Commonly, tests for urea or serum creatinine are performed. Crea-
tinine tests are used to calculate a filtration rate for the kidneys, the estimated glomerular
filtration rate (eGFR). An eGFR of less than 90 ml / min is indicative of CKD. Simi-
larly, urine tests commonly assess levels of creatinine and albumin. The ratio of albu-
min:creatinine, the ACR ratio, can be used to further assess kidney function. Imaging
such as or computational tomography (CT) can be used to assess blockages in the renal
artery, which can be another cause of kidney failure, and ultrasound can be used to iden-
tify other causes of renal failure such as nephrocalcinosis [23]. Biopsies are also used for
cellular examinations of kidney tissue.
CKD can be categorised into five stages, depending on the eGFR:
• stage 1 (G1) a normal eGFR (above 90ml/min), with other indications of kidney
disease;
• stage 2 (G2) a slightly reduced eGFR (60-89ml/min), with other indications of
kidney disease;
• stage 3a (G3a) an eGFR of 45-59ml/min;
• stage 3b (G3b) an eGFR of 30-44ml/min;
• stage 4 (G4) an eGFR of 15-29ml/min;
• stage 5 / ESRD (G5) an eGFR below 15ml/min
CKD stage 5 / ESRD indicates that the kidneys have lost almost all their function.
Similarly, staging exists for concentrations of albumin:creatinine, provided from the
ACR ratio. Increasing concentrations indicate increasing severity of kidney damange:
• stage 1 (A1) Optimum and high-normal ACR <29;
• stage 2 (A2) High ACR 30 - 299;
• stage 3 (A3) Very high ACR > 300
An informative graphical interpretation of these disease stages is provided by Levey et al
[93], see figure 1.2.
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Figure 1.2: CKD stages and associated risk. Colours indicate relative-risk for the set of outcomes all-
cause mortality, cardiovascular mortality, kidney failure treated by dialysis and transplantation, acute kidney
injury, and progression of kidney disease, (Levey et al, [93], Elsevier)
Symptoms of CKD can include high levels of urea in the blood, high levels of phos-
phates in the blood, blood presenting in the urine, and fatigue, but CKD can also develop
insidiously with no symptoms, and it is not uncommon for patients presenting with ill-
health to be diagnosed with CKD or ESRD and require RRT immediately. However, it is
difficult to predict which patients will develop ESRD, and not all patients with CKD will
progress to ESRD.
1.1.5 Risk factors and causes
Risk factors for ESRD are both non-modifiable and modifiable. Age, acute kidney in-
jury, cardiovascular disease, renal tract disease, socio-economic status and family history
are non-modifiable risk factors for developing ESRD. Modifiable risk factors have been
identified including smoking, alcohol and drug consumption, obesity, and chronic use of
non-steroidal anti-inflammatory drugs. Diabetes and hypertension are modifiable, but not
curable risk-factors for ESRD development. Appropriate management of these conditions
can help minimise the impact of these conditions.
Diabetic nephropathy causing glomerulonephritis is the most common cause of ESRD
world-wide and affects around 15- 40 % of patients with type-1 diabetes [66], and 5-20
% of patients with type-2 diabetes [66, 1]. Diabetic nephropathy can be characterised
histologically, typically presenting nodular glomerulosclerosis, tubulointerstitial fibrosis
6
and atrophy. Interstitial causes refer to interstitial nephritis, which is a condition affecting
the interstitium of the kidneys, manifesting as inflammation of the spaces between kidney
tubules. Most commonly, interstitial nephritis is caused by a reaction to medications,
in particular analgesics or antibiotics. Multi-system causes generally indicate conditions
such as systemic lupus erythematosus, which may have implications on kidney function.
During the period 2012-2016 in Scotland [165], the most common cause of starting RRT
was due to diabetic nephropathy (28 %), followed by interstitial nephritis (22 %), and
multi-system (22 %) causes.
1.1.6 Co-morbidities
ESRD increases in likelihood with age, and is therefore most likely to occur in a setting of
pre existing co-morbid conditions. Hypertension, diabetes, ischemic heart disease, heart
failure, peripheral vascular disease, cerebrovascular disease, chronic respiratory disorder,
depression, thyroid disorder and anaemia are common co-morbidities in patients with
CKD-3 [42]. These co-morbidities may impact on treatment burden, medications man-
agement, quality of life, and survival of patients [104, 69, 53].
Cardiovascular causes were the leading cause of death in patients receiving RRT in
2016 in Scotland, accounting for 30 % of deaths. A large study performed in 2006 ob-
served high incidence of co-morbidities such as anemia, coronary artery disease, conges-
tive heart failure, diabetes mellitus, hypertension, hyperlipidemia, and peripheral vascular
disease in a group with eGFR less than 90 with a higher rate of mortality, when compared
to an age and eGFR matched index group with lower mortality [58]. They found that
co-morbidities most strongly associated with death were congestive heart failure, anemia,
proteinuria, and peripheral vascular disease. Due to the presence of these co-morbidities,
patients with CKD are more likely to die than progress to ESRD [53].
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1.2 Treatment
Any treatment for ESRD is designed to reduce or reverse the uremic syndrome of patients,
reduce the concentration of blood-borne toxins, and restore the fluid balance of the patient.
This involves replacing the kidney function, through either transplantation, or dialysis.
Transplant is the preferable option, but is limited in availability. Dialysis is more available,
but requires a significant change in a patient’s life style.
1.2.1 Transplant
The most successful treatment for ESRD regarding patient quality of life is transplantation
of a donor kidney. In 2016 in Scotland, the most common form of RRT was transplanta-
tion, which counted for 57 % of treatment [165]. Donors were primarily cadaveric, with
82 % of transplantation coming from cadaveric donors over the 2012 - 2016 period.
Current Scottish data shows transplant / graft survival at approximately 95 % at one-
year, 87 % at five-years and 74 % at ten-years in Scotland [165]. In 2015, 1-year survival
for patients who had received a transplant was 97.1 %. Most recent data for 5 and 10-year
survival shows rates of 90.6 % and 75.7 % respectively.
1.2.2 Dialysis
The term dialysis refers to “diffusion across a semipermeable membrane”. Dialysis treat-
ment relies on some form of membrane which allows diffusion of waste products out of
the blood. Two main forms of dialysis exist, peritoneal dialysis, and haemodialysis.
Peritoneal dialysis (PD) is a corporeal dialysis, which makes use of a natural cavity
in the body, the peritoneal cavity. During PD, the peritoneal cavity is used as a storage
space for around 2.5 L of dialysate (see figure 1.3). The peritoneum is a semi-permieble
membrane which allows diffusion of blood-borne waste products into the dialysate fluid.
Due to the presence of many arteries and veins in the peritoneal cavity, diffusion occurs
readily into the dialysate fluid.
Dialysate fluid is placed in this cavity through a catheter, which is then regularly used
to add and remove dialysate fluid. Waste products filter into the dialysate fluid through
diffusion, and excess water is removed via osmosis. The dialysate requires regular chang-
ing, and patients are commonly trained to perform this themselves. Peritonitis is a com-
mon complication from PD, with reports of a rate of one incident every two years [155].
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Figure 1.3: During peritoneal dialysis, the dialysate fluid is placed in the peritoneal cavity through a catheter
(Circle Medical Management)
Complications arising from the catheter are a significant source of morbidity for patients
undergoing PD, and can lead to a change of RRT to haemodialysis. PD is the least com-
mon form of RRT in Scotland, with only 6 % of patients treated by PD in 2016 [165].
PD is more common in the rest of the UK, accounting for 10 % of patients in northern
Ireland, 9 % in wales and 7 % in England [147].
Haemodialysis (HD) refers to dialysis of the blood, and is an extra-corporeal tech-
nique. HD involves rerouting a patients blood through a machine which replicates the
function of the kidney. The machine removes unwanted products and excess water from
the blood. Diffusion across a concentration gradient allows a dialysis machine to remove
excess solutes and fluid from the blood.
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Figure 1.4: Diffusion across the semi-permeable membrane attempts to reach equilibrium between blood
and dialysate. Water, and various toxins such as urea diffuse out of the blood, and essential minerals such
as sodium diffuse into the blood.
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A continuous stream of dialysis fluid is passed in the opposite direction of the blood
flow in order to create the concentration gradient. The dialysis fluid contains a buffer and
electrolytes which diffuse in the direction of the blood, as in figure 1.4. Excess water is
removed through pressure filtration of the blood as it passes through the dialysis machine,
this is known as ultrafiltration, although this is not always routine.
Figure 1.5: In the dialysis schematic, blood leaves the body from an arterial site in the vascular access.
Anticoagulants are administered to prevent clotting in the machine. The hemofilter contains the semi-
permeable membrane where diffusion occurs to rectify the uremic state of the blood. If needed, fluid content
is replaced in the blood. Air monitors are used to remove bubbles in the blood, and pressure monitors used
to screen for stenosis. Filtered blood is then returned to the body at the venous site.
Typically patients receive treatment 3-4 times a week, for 3 hours a session. The
adequacy of HD is typically measured using a ratio, Kt/V . K represents the clearance, t
the time spent dialysing, and V the volume of water a patient’s body contains. The urea
reduction ratio (URR) is another test used to determine the adequacy of dialysis:
URR =
UreaPre − UreaPost
UreaPost
× 100 (1.1)
Ideally, the URR should be 70% or over.
HD is the second most common form of RRT in Scotland, with 37 % of patients in
2016 receiving hospital HD, and 1 % of patients receiving home HD. HD prevalence is
similar in the rest of the UK, accounting for 20 % of patients in northern Ireland, 26 %
in wales and 30 % in England [147]. HD will typically last until transplant or death, as
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kidney function is unlikely to recover. Median survival times for patients on HD have
been reported as 4.4 - 4.8 years [127], and five-year survival of around 50 % [181].
It is desirable to have a high blood flow pass through the machine, as this reduces
the time patients need to receive treatment. Typically blood flows used are around 400
ml/min, and are taken and returned via a vascular access (VA). Blood is taken from an
arterial site, and returned to a venous site. The VA must be able to provide the flow
needed, as well as be able to support the large needles used - typically 15-17 gauge. VA
problems are the main source of morbidity in patients undergoing RRT, but different forms
of VA are associated with different rates of morbidity. Three main forms of VA exists,
with their respective benefits and problems: the central venous catheter, the arterio-venous
graft and the arterio-venous fistula.
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1.3 Vascular access
1.3.1 The Arterio-Venous Fistula
The Arterio-Venous Fistula (AVF) revolutionised vascular access by allowing repeated
access to an autologous high flow vessel. Pioneered by Brescia and Cimino, the AVF is
a surgical anastomosis between an artery and a vein [24]. In the original paper, a side
to side anastomosis of the vessels in which the sides of an artery and a vein are stitched
together using arterial silk is described. Other geometries of the anastomosis can be seen
in figure 1.6.
Figure 1.6: Four different types anastomotic configurations: A) Side-to-side anastomosis, B) End-to-end
anastomosis, C) End-to-side anastomosis, and D) Side-to-end anastomosis [20]
AVFs vary by placement site, with potential sites located in the wrist (radio-cephalic
(RC)) on the non-dominant arm, by the elbow (brachio-cephalic (BC)) or in the upper
arm (brachio-basilic transposition (BB)) - see figure 1.7. AVFs created in other limbs
are possible, such as in the legs. Distal AVF locations (such as the wrist) are commonly
chosen as the first access, as failure in these still leaves the possibility of more proximal
locations such as the BC-AVF [85]. Venous valves are not commonly considered, as
blood-flow continues in the natural direction, thus valves are typically left alone.
The best outcomes have been observed when patients initiate HD with an arteriove-
nous access [135], and this is reflected in guidelines stating patients should ideally start
HD with an AVF [85, 166]. UK Renal Association standards indicate that 60 % of pa-
tients should commence HD with an AV access, and 80 % of patients should dialyse with
an AV access [85]. Over the period 2012 - 2017 in Scotland, approximately 45 % of pa-
tients started HD with an AV access [165]. However, as of 2017, 72.9 % of patients were
receiving HD via an AV access, primarily a fistula. This indicates that a large number of
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Figure 1.7: Multiple types of AVF are possible in the fore-arm. The radio-cephalic is typically the first
choice, as failure leaves the brachio-cephalic and brachio-basillic viable for further attempts (Laminate
medical technologies)
patients are having an AV access created after initialising HD. It is possible that poorer
access outcomes for other modalities are due to the slightly different demographic of pa-
tients requiring immediate access typically through a catheter: they may be crash-landers
presenting to clinic with low renal function requiring immediate HD, or they may have
required catheter usage due to failed AV access or poor vessel quality.
1.3.2 Central venous catheters
A central venous catheter (CVC) is an access which uses the large veins as a blood source
for HD. A CVC is inserted through the skin, before being placed inside the internal jugular
vein (see figure 1.8). Subclavian access is also possible, but is less common. The external
limbs of the CVC are then connected to the dialysis machine.
CVCs fulfill basic emergency requirements, and no is surgery required to place the
CVC. No waiting post dialysis for bleeding to stop is required, and access to blood is
instant. Placement in the large veins removes the requirement of functional peripheral ve-
nous vessels (as is required for other forms of VA), which certain patients may lack. There
are many vessels which can support a CVC, and it is also generally the most comfortable
access for a patient due to relatively painless and easy use [59]. CVCs are generally used
as a shorter term option before placement of an arteriovenous graft (AVG) or AVF, but
initial HD with a CVC has been linked to future problems with VA - likely caused by
central venous stenosis[151].
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Figure 1.8: CVC placement is possible in the subclavian or the internal jugular. Internal jugular is preferred
as complications with stenosis are less severe on fistula function (Michigan Institute)
However, due to higher overall mortality [46], CVCs are the least preferred VA for
HD. In particular, long-term CVC use is associated with a myriad of problems including
thrombosis, central vein stenosis and and serious catheter related infections [59]. Again,
the higher mortality is likely explained by the differing patient demographic. Patients re-
quiring immediate HD will likely have poorer outcomes than patients with time to prepare
for RRT.
1.3.3 Arteriovenous grafts
An AVG is an artificial tube (polytetrafluoroethylene) connecting an artery and a vein.
Blood is taken from, and returned to the tube during dialysis. AGVs are associated with
a ten times higher rate of infection than arteriovenous fistulas, due to the introduction of
foreign material in the body [156]. AVGs are beneficial when a patient has poor peripheral
vessels, and can be unsuitable for fistula creation [151]. AVGs are typically ready for use
within one-month of placement [14], but early cannulation grafts can be ready for use
within as little as 72 hours [158].
AVGs are more likely to occlude than the arteriovenous fistula, and offer lower long-
term patency. The most common causes of failure for AVGs is intimal hyperplasia and
stenosis on the venous anastomosis [14]. A systematic review of AVG patency rates found
72 % primary patency at 6 months and 51 % at 18 months [68].
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Figure 1.9: An AVG is an artificial tube connecting an artery and a vein, used to provide blood for HD (Kim
et al [75], Scientific Research Publishing)
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1.4 AVF Maturation and Failure
1.4.1 Physiological changes after AVF creation
In the landmark paper by Brescia and Cimino the arterio-venous fistula was first described
[24]. They described an immediate palpable thrill at the site of the fistula, and attempted
dialysis the day after surgery (which is no longer the common case). The vein is describe
in this case as undergoing ‘arterialisation’, due to medial thickening. The main physio-
logical changes which occur after AVF creation are vessel dilation, and flow increases.
Interestingly, with 13 patients and over 800 total dialysis sessions, Brescia and Cimino
reported extremely good outcomes, with only one fistula failing to function. Modern AVF
usage does not reflect these results.
At rest, mean normal blood flow in the brachial and radial arteries are 50 and 25ml/min,
increasing around 3-5 times with exercise. Healthy brachial arteries have been shown to
be around 4mm [173], and the radial artery lower at around 2mm [180]. Arterial flow is
characterised by its triphasic waveform when imaged with doppler ultrasound (see figure
1.10). Venous flow is typically much lower in the peripheral vessels, and is steady-state.
Figure 1.10: Doppler US image of a healthy brachial artery showing typical tri-phasic arterial flow
Creation of the AVF causes arterial blood to by-pass the higher resistance arterioles
and venules. This creates a lower resistance pathway for arterial blood to return back
to the heart through the arteriovenous anastomosis. As a result of the increased forward
flow and decreased resistance, the artery loses its typical tri-phasic flow pattern. AVFs
exhibit continuous forward flow, with a higher peak-systolic velocity and end-diastole
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than is normally exhibited in the arteries. This results in a larger share of total blood
passing through this newly created circuit. The larger blood volume results in a higher
radial pressure exerted on the vessels. Clinically successful fistulas have arterial flows
of at least 600ml/min, and in order to accommodate this flow, the artery should ideally
dilate. Previous studies have described arterial dilation of 40-50% [44, 98].
Pouseuille’s law demonstrates that blood flow (Q) with a viscocity n is proportional
to the pressure gradient (∆P ) and vessel radius (r):
Q =
r4
n
×∆P (1.2)
Pouseuille’s law would predict an 80 % dilation to achieve a 10 times higher blood flow, as
is required in the arteries and veins of AVFs. Previous studies have described arterial di-
ameter increases of 40-50%[44, 98] following AVF creation. Lomonte et al [98] observed
that arterial diameters increased by 41.9 % and blood flow rate by 1182 % at 28 days com-
pared to the baseline values taken pre-surgery. Demmers et al [44] also demonstrated an
increase in radial wall thickness over a year following RC-AVF placement. Lower than
expected dilation can be explained by a larger than expected pressure gradient caused by
pulsatile flow, and a lowering of blood viscosity at higher flow velocities.
Venous diameter and flow has been shown to steadily increase after AVF creation.
Robbin et al [150] found venous flow in both lower and upper arm AVFs to reach 50%
of its 6-week flow value one-day post AVF creation, and most AVF veins to reach 4 mm
in size after 2 weeks, increasing from an average of 2 mm for lower-arm AVFs. Contrary
to Brescia and Cimino, Corpataux et al [39] found that the vein wall thickness remained
constant, indicating an increase in the tissue mass of the vein. This process of dilation and
increasing flow is termed maturation of the AVF, and ultimately is the process by which
the AVF becomes suitable for dialysis.
1.4.2 Effect of wall shear stress
A major stimulus in AVF remodelling is the increase in shear stress at the vessel wall,
known as wall shear stress (WSS) [129]. Wall shear stress is a frictional force applied
tangentially to a vessel wall, due to some flow (see figure 1.11). Wall shear stress (τ ) is
described by the Haagen-Poisseuille equation:
τ = 32n
Q
Πd3
(1.3)
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where Q is the mean flow rate, n is the viscosity and d is the diameter of the vessel. The
increased flow from AVF creation results in an increased WSS in both vessels, and has
been verified in vivo [146].
Figure 1.11: WSS (τ ) located at the endothelial layer, and pressure (ρ) directed perpendicularly to the vessel
wall. WSS is confined to the endothelial layer and follows the direction of flow (Macmillan Publishers Ltd)
WSS is confined to the endothelial layer in blood vessels, and enodthelial cells can
respond to changes in WSS levels. The increase in WSS causes endothelium cells to
release vasodilating mediators such as nitrous oxide (NO) [46]. These agents act to in-
crease the diameter of the vessel, in an attempt to reduce WSS values to their baseline
value. Dammers et al [44] observed that WSS values in AVFs are never truly normalised
to baseline in both radial and brachial arteries, despite the vessels increasing in diameter.
There is strong evidence suggesting that AVF maturation is dependant on a healthy
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endothelium [128]. It is well established that arterial dilation as a response to an in-
creased flow is due to the endothelial response [40, 171, 4]. Owens et al [128] linked
endothelial function to the percentage of arterial and venous remodelling experienced af-
ter fistula creation, by measuring flow mediated dilation (FMD). Brachial artery dilation
post-AVF creation was positively correlated with endothelial function as measured by
FMD. Impaired endothelial function is associated with a decreased vasodilation effect,
from lower production of NO [60]. Endothelial function is widely variable in patients
with CKD [5], so the extent of its influence requires further study and in more controlled
circumstances[96].
Computational fluid dynamics (CFD) simulations of AVFs using patients’ medical
images have been used to assess blood-flow patterns and WSS in AVFs. These studies
have attempted to draw conclusions between these metrics and the clinical outcome of an
AVF. Typically, a patient’s medical images are used to create stylised 3D geometries of the
patient’s AVF. Computational solver packages are then used to solve the Navier-Stokes
equation, which describe the flow-distributions inside containers. He et al [63] studied
one fistula at multiple time-points in order to create a pipeline for using computational
simulations. They were able to locate an area of stenosis, and observed that it correlated
to an area of high wall shear stress in their model. It was also demonstrated that WSS
continued to decrease throughout the length of the study - up to 7 months after creation.
A study by Sigovan et al [161] tracked vessel cross sectional area over a number of months
for 3 patients, showing increases in the venous and arterial segments over three months
(see figure 1.12). They observed that flow patterns in the curved regions of the AVF were
associated with higher values of WSS on the outer curve wall, and lower WSS values on
the inner curve wall, and that low WSS areas were commonly sites of recirculation.
WSS is the parameter that has received the most attention in these simulations. A
meta-analysis by Browne et al [26] identified 15 studies which investigated the role of
WSS in fistula maturation using CFD. They conclude that the studies show that configu-
ration of the AVF, vessel wall thickness, and the reduction of shear stress all contribute to
maturation.
20
Figure 1.12: Measurement of vessel area over a 3-month time period, using 3D models of the AVF derived
from MRI images (Sigovan [161], Biomedical Engineering Society)
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1.4.3 The AVF for haemodialysis
A fistula is deemed ready for dialysis when it produces an appropriate flow to support
dialysis and the venous segment is an appropriate diameter for cannulation. The rule
of sixes [159] is commonly cited as a general set of criteria for a mature fistula, and is
presented in table 1.1. The rule of sixes gives the criteria that flow should be at least 600
ml / min, the vessel diameter should be at least 6mm, and the depth of the fistula should
be less than 6mm.
Fistula Flow 600 ml / min
Cannulation segment diameter >6mm
Cannulation segment length 10cm long or 2 segments of 4cm
Depth of fistula <6mm from skin surface
Table 1.1: Rule of sixes, giving properties of a “mature” AVF [159]
Kidney Disease Outcomes Quality Initiative (K-DOQI) guidelines recommend that
AVFs are planned 6 months prior to the start of dialysis [85]. The clinical success of an
AVF depends on its ability to be cannulated and support dialysis. This depends on the
dilatory ability of the vessels, as well as the development of a high-flow. A good fistula
will provide a high flow, be easily cannulated, and cause minimal problems for patients.
As long as none of these criteria are broken, an AVF will not require an intervention. Even
if a stenosis develops in the fistula, if it does not affect the flow, there is no need for an
intervention. Due to the time period required before an AVF is suitable for HD, forward
planning is essential if patients are to commence HD with an AVF.
AVFs are the preferred method of vascular access due to lower occlusion and infection
rates. Long-term patency from AVFs is shown to be higher than for both AVGs and CVCs
[135]. A meta-analysis by Almasri et al observed higher mortality in patients dialysing
with a CVC when compared to AVFs and AVGs [7], and also demonstrated that highest
long-term patency is achieved when using an AVF.
AVFs still suffer from relatively high failure rates. Meta-analyses have found average
1-year patency rates of around 60%, meaning around 40% of AVFs are inadequate to
sustain dialysis for a year without intervention [7, 152, 3]. Multiple studies have been
conducted comparing patency rates of the different forms of AVF. In 2004, Rooijens et
al highlighted high failure of RC-AVFs using meta-analysis of 38 studies. They 1-year
primary (time from creation until intervention) and secondary (time from creation until
abandonment) patency rates of 62.5% and 66% respectively. In 2014, another review
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found that the picture was much the same [3]. Primary patency at 1-year was found to be
60%, dropping to 51% at 2-years. Secondary patency increased slightly to 71% at 1-year
and 64% at 2-years.
Failure of an AVF can cause additional catheter insertion or missed dialysis sessions
for patients. AVF failure can broadly be categorised into ‘failure to mature’ ‘late AVF
failure’ and ‘primary failure’. Certain AVFs will never reach a point where they can be
used for HD (failure to mature), and others will be useable for HD, but later occlude
secondary to stenosis (late failure). Primary failure describes a fistula that is unsuccessful
at creation due to surgical implications or disease. Typically, failure to mature will arise
due to poor flow development in the fistula as a result of sub-optimal arterial or, more
commonly, venous dilation. The most common cause for late AVF failure is due to neo-
intimal hyperplasia (NiH) leading to stenosis or thrombosis. Dixon et al [46] provide a
graphical interpretation of the possible processes leading to failure to mature or late AVF
failure, see figure 1.13.
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Figure 1.13: “The figure depicts the temporal pattern [...] of [...] fistula maturation in a radiocephalic fistula.
The top of the figure shows the preoperative flow and pressure in the radial artery and cephalic vein... The
middle two figures depict the situation 1 day after fistula creation for a fistula that has dilated rapidly and is
likely to mature (left) or one that has not dilated sufficiently and is likely to fail (right). The middle graph
inset shows that after creation of the low-resistance circuit, volume flow rate remains high and significantly
above zero throughout both systole and diastole. Thus, the mean volume flow rate is much greater than
predicted for the extent of arterial dilation by Pouseuilles law[...] The three figures at the bottom depict the
situation at 48 weeks after fistula creation for a successful fistula (left) or two possible modes of early fistula
failure the development of a juxta-anastomotic stenosis (middle) or impaired dilation (right). Between 20
and 50% of radiocephalic fistulas will fail to mature and between 65 and 100% will have evidence of a
stenosis.” (Dixon [46], International Society of Nephrology)
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1.4.4 Failure to Mature
Failure to mature typically means that the AVF cannot produce a flow which is suitable for
HD. Inadequate venous dilation can restrict the flow passing through the venous segment,
commonly manifesting in failure to mature. Accessory veins can also contribute to poor
venous flow in the venous AVF segment due to the sharing of the total blood flow, but
can be easily ligated during AVF creation. Calcification has been seen in the veins of
patients with CKD, which may reduce the ability of the vein to dilate, similar to a calcified
artery [139]. However, the exact mechanisms which may impair venous dilation are not
currently understood.
Another possible mechanism for AVF failure to mature is poor arterial dilation. If the
artery cannot dilate adequately, a high flow-rate may be hard to achieve. When assessed
by FMD, patients with CKD are shown to have reduced endothelial function [186], which
limits the dilatory ability of the artery. Similarly, the presence of arterial calcification
[139], which increase vessel stiffness, has been shown to reduce the vessels dilatory abil-
ity [18]. Low arterial elasticity has been linked to reduced maturation, in a small cohort
study by Kheda et al [74], however the mechanisms were not determined. This study also
observed that small arteries dilate less (% diameter increase) than larger arteries, regard-
less of AVF type. A study in 2016 by Masengu et al [103] observed no relation between
arterial elasticity as measured by pulse wave velocity and AVF outcome.
1.4.5 The Effect of Stenosis and Occlusion
The main antagonist to outward remodeling is NiH - the thickening of the vessel walls,
resulting in decreased lumen diameter [140] (see figure 1.14). NiH can lead to stenosis,
which can lead to a reduced flow, or thrombosis [91]. It is hypothesised that upstream
events such as vascular injury during AVF creation or other endovascular procedures
causes the downstream biological response which allows for the development of NiH
[91]. NiH is common after endovascular procedures, and in some cases is a physiological
healing response to reconstructive procedures [82].
Multiple studies have assessed the relationship between WSS, flow, and NiH in an ar-
ray of vessels, including the AVF. In 1983 the presence of low WSS, caused by flow sepa-
ration and recirculation (see figure 1.15), was linked to increased IMT and arteriosclerosis
in the carotid artery [189]. In 1985, Ku et al [83] again found positive correlation between
low WSS and increased intima-medial thickness (IMT) in the carotid, but also found pos-
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Figure 1.14: NiH can cause stenosis leading to dysfunction in a mature or developing fistula (Rothuizen
[153], with permissoin from Oxford University Press)
itive correlation between oscillations in the direction of WSS and IMT. CFD studies have
linked regions of abnormal WSS, such as those caused by flow separation, recirculation
and vortexes, with the characteristic sites of NiH and stenosis in AVFs [50]. A review by
Browne et al [26] suggests that outward remodelling occurs in the AVF to reduce WSS
levels, and that particularly low, or oscillating levels of WSS are associated with inward
remodelling.
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Figure 1.15: Changes in vessel geometry can affect flow-patterns in both arteries and veins. Branches such
as at the carotid bulb are associated with areas of high WSS and disturbed flow. EC : endothelial cell
(Macmillan Publishers Ltd)
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Access type Common sites of stenosis
radio-cephalic fistula juxta-anastomotic segment
brachio-cephalic fistula cephalic arch
Brachial arterytotransposed basilic fistula transposed vein segment
Table 1.2: Common sites of AVF stenosis [141]
Most AVFs which do not function as intended for HD are found to have at least one
lesion if imaged [16]. These stenotic lesions can be functionally important, reducing
flow, or can be benign and have little effect on HD. If severe, stenosis can restrict flow in
a young AVF causing a failure to mature, or it can occur once a fistula has matured and is
being used for HD, resulting in late-AVF complications.
Most frequently, stenosis occurs around the anastomotic area. Quencer and Arici
[141] described the common sites of stenosis in RC, BC and BB-AVFs, as shown in table
1.2, and figure 1.16. Inflow stenosis can have the effect of restricting flow, and subsequent
maturation in a new AVF, or limiting flow and causing occlusion in a mature AVF. Outflow
stenosis, such as in the cephalic arch, can cause aneurysmal dilation, a pulsatile, tense
AVF, and poor flow.
In the RC-AVF the juxta-anastomotic stenosis is the most frequent observation, but
this site is also common in BC-AVFs [142]. BC-AVFs are reported to suffer from an
increased number of cephalic arch stenoses, with rates between 30 - 77 % reported in
dysfunctioning fistulas [142, 143]. BB-AVFs are reported to have a large number of
stenoses in the venous swing-site, which has commonly been transpositioned in order to
create the fistula [143]. Literature reports that around 70 % of stenoses in these fistulas
occur at the swing-site.
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Figure 1.16: Characteristic sites of AVF stenosis (Quencer and Arici [141] American Journal of Roentgenol-
ogy)
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1.5 Preoperative assessment
1.5.1 Clinical Assessment
In a bid to increase AVF patency rates, pre-operative assessments of the blood vessels
are performed. KDOQI guidelines recommend physical examination using assessments
of the vessels such as palpitation. Allen’s test is common, where the speed of blood
reperfusion after occlusion is used to assess the circulation. Medical history of the patient
is also assessed, recording the presence of co-morbidities and risk-factors for AVF failure
such as diabetes and hypertension, and patients are screened for the use of previous CVCs
and other radiological or surgical interventions.
This information alone can be enough to determine a fistula site, but subtle features
can be missed, such as narrowings or calcification of the vessels. Clinical assessment does
not allow determination of the type of flow, the presence of thrombus in the veins, and
does not allow verification of vessel uniformity through its length. Central vein stenosis
can be missed during clinical evaluations, as well as problems downstream where the
vessels become less superficial.
1.5.2 Ultrasound assessment
Pre-operative ultrasound (US) assessment examines the morphology and flow of the veins
and arteries that can be used for AVF creation [6]. Pre-operatively, arteries can be as-
sessed for patency and phasicity - with commonly only triphasic (normal) waveforms as
acceptable criteria. The diameter is also recorded with adherence to minimum criteria
established by the local clinic. The degree of calcium can be qualitatively assessed. Veins
can be assessed for patency, diameter and uniformity, with reductions in diameter indica-
tive of possible stenosis. Thickened venous wall in isolated segments, which can lead to
stenosis, can be identified. The number of branches in relation to possible anastomotic
sites, which may reduce flow through the fistula, can also be identified via US.
Multiple studies have shown US mapping to not only increase placement, but to in-
crease patency rates. Allon et al [6] cited increased placement and increased patency
rates for fore-arm AVFs after introducing US screening, and Robbin et al [149] reported
similarly, and included a reduction in unsuccessful surgical explorations. However, not
all studies show positive results. A study by Patel et al [131] found a reduced maturation
rate after introducing mapping, but they note that this may be due to secondary access
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sites being used as a result of mapping. A meta-analysis by Georgiadis [55] found that
mapping reduces immediate failure, and a non-significant trend pointed towards reduced
long-term failure.
Ultrasound measurements of vessel diameter are perhaps the most widely-known risk-
factor for AVF failure. Techniques vary, but for example, the measurement can be made of
the narrowest region of a certain length of vessel, or at a certain point such as a bifurcation
point. Numerous studies have addressed the question of what is the minimum diameter
of a vessel acceptable for AVF creation, and can not agree on the lower limit (see table
1.3). For RC-AVFs, minimum cephalic vein diameter for creation has been reported in
the range of 1.5 mm to 2.5 mm, with meta-review [79] suggesting the best outcomes
are observed when the diameter is over 2 mm. This meta-review does not recommend
creating an RC-AVF with a cephalic vein below 1.5 mm [79]. Radial artery diameters are
reported in the range of 1.5 mm to 2.4 mm, with the most common being at least 2 mm.
Similarly, meta-review reports the best outcomes when the radial artery is over 2 mm, and
that they should not be created with arteries below 1.5 mm in diameter [79]. In upper arm
AVFs, recommended criteria for BC or BB-AVF creation have been recorded as arterial
diameter over 2 mm, and vein diameter of over 2.5 mm [105, 43].
Study Diameter lower limit
Dageford [43] vein <2.7 mm in BB and BC-AVF
Nakata [122] radial artery <2 mm
Bashar [15] vein <2.5 mm for all AVF
Sahasrabudhe [154] vein <2 mm in BB and BC-AVF
Parmar J. [130] radial artery <1.5 mm
Table 1.3: Variance in vessel lower limit for AVF creation from literature
Vessels which appear large enough on US and show no obvious problems (such as
in figure 1.17) can still fail to mature. The continued failing of AVFs with ‘good’ ves-
sels indicate that there are additional factors influencing the outcome, but there is limited
knowledge as to what these factors are, or if pre-operative tests can identify them. Ultra-
sound still presents itself as a good modality to conduct the pre-operative assessment due
to its relative ease of use, availability, and accuracy. Ideally, a preoperative test should be
able to quickly assess important markers of AVF failure, with minimal disruption to the
patient’s life.
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Figure 1.17: B-mode ultrasound image of a healthy patent brachial artery
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1.6 Post-Operative Surveillance and Interventions
1.6.1 Post-operative Ultrasound
Surveillance describes a qualified individual performing a regular examination on a pa-
tient’s vascular access. The goal of surveillance is to identify sites of potentially clinically
relevant stenosis, allowing pre-emptive treatment. Treating these sites early may prevent
the failure of the access, and requirement of an alternative access site or modality. Post-
operative surveillance can be used to detect subclinical stenosis in all accesses, not just
AVFs.
Multiple trials have found that US based surveillance reduces the incidence of throm-
bosis, improving patency rates. Aragoncillo et al [12] reported improvement in throm-
bosis free patency in a surveillance group (p = 0.03), and an increased patency rate (p
= 0.01), compared to a control group during a 3-year multicenter randomised controlled
trial (RCT). A 5-year RCT by Tessitore et al [170] reported that surveillance, along with
pre-emptive interventions could reduce thrombosis rates (p = 0.03) and prolong functional
patency rates (p = 0.001). In a single centre RCT, Han et al [61] reported a decrease in fail-
ure to mature rates in a group undergoing US surveillance compared to a control group
through the use of early/pre-emptive interventions (non-significant, p = 0.1). A meta-
review of post-operative surveillance practice found strong evidence that surveillance can
decrease the risk of thrombosis in a patient’s AVF [174], however no evidence was found
for predicting thrombosis in patients with an AVG.
Typically, an US post-operative procedure (see figure 1.18) consists of assessing the
arterial inflow, the anastomotic region, and the venous outflow tract of the AVF. Vessel
diameters will be assessed using B-mode US in both longitudinal and radial views of the
vessel. Blood-flow measurements are also taken in these areas. Aliasing on a colour
doppler image can indicate stenosis, due to the presence of high-veloicty jets [133].
A major benefit of US in the post-operative surveillance of an AVF is the increased
knowledge of the underlying issue causing AVF dysfunction, which reduces need for
invasive assessments to determine the cause. This can result in a reduction of emergency
care including CVC placement, or invasive thrombectomy procedures.
33
(a) Stenosis detection on B-mode US showing an area of stenosis as indicated by the *
symbol
(b) Stenosis detection on colour doppler US showing aliasing from the high flow jet
Figure 1.18: Stenosis detection on US from both (a) B-mode and (b) doppler imaging. Stenosis are com-
monly defined by their percentage reduction in diameter, i.e. a 50 % stenosis would indicate a diameter
reduction of 50 % at the site of stenosis.
34
1.6.2 Interventions on a failing access
The goal of any intervention on a VA is to maintain, or re-establish patency so the VA can
be continued to be used for HD. Best practice guidelines recommend treating a stenosis
if the diameter is reduced by over 50 %, and the access flow is reduced. Percutaneous
transluminal angioplasty (PTA) (see figure 1.19), is the typical treatment for VA stenosis.
Access to the vascular system is achieved percutaneously, and imaging is used as guid-
ance to control the catheter placement, and ensure it reaches the treatment area. The first
step in the technique is to use a guidewire to deliver the catheter to the location of the
stenosis, through cannulation of a vessel. The delivery method will differ for different
stenosis morphology, and surgical experience [176]. Once the catheter has reached the
desired location, the balloon is inflated, which is potentially painful, and patients can be
administered an analgesia. Balloon profile chosen depends on the non-stenotic diame-
ter of the vessel [124]. Depending on the stenosis, and the dilation required, different
balloons can be employed, with higher pressures, or balloons which contain small metal
blades, known as cutting balloons. Cutting balloons possess atherotome blades which
produce “controlled incisions” into the venous wall during inflation [124].
Digital subtraction angiography (DSA) is performed concurrently with balloon inser-
tion, in order to visualise the stenosis, and assess if the intervention was successful [121].
If inadequate dilation has been achieved, the PTA can be repeated with another balloon.
The interventional radiology technique has a high learning curve, and not all centres can
provide this treatment 24 hours a day, and sometimes patients must be transported for
treatment.
If VA thrombosis occurs, it should be treated as soon as possible to avoid the need for
access via a CVC. Thrombolysis is typically performed mechanically, with a thrombec-
tomy catheter. The device is used to remove the blood-clot, restoring patency in the vessel.
The area can also be treated with balloon angioplasty after thrombectomy.
Stent usage is a further option, and can be used in cases of stenosis, aneurysm, pseudo-
aneurysm, and in cases of angioplasty induced vascular rupture [56].
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Figure 1.19: DSA image showing balloon catheter insertion and inflation at a stenosis site. Some residual
stenosis is still evident post-dilation at the venous anastomosis.
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1.7 Risk Factors for AVF Failure
1.7.1 Known Risk Factors
As discussed, vessel diameters from US are commonly the deciding criteria on AVF cre-
ation. Many studies have observed that AVF failure rates are increased when using lower
diameter vessels (see table 1.3). However, these studies cannot agree on a lower limit for
vessel sizes, and vessels used above these limits can still fail to mature.
Besides vessel diameters, numerous demographic factors have been identified in the
literature as risk-factors for AVF failure. Most commonly, old age, race, gender and
diabetes have been found to have a negative impact on AVF patency rates.
A landmark study by Hod et al [64] included over 20000 patients and found a number
of risk-factors for AVF failure, including older age, female gender, black race, diabetes,
cardiac failure, and duration of pre-ESRD nephrology care. They suggest that in at risk
patients, for example elderly African-American women, that perhaps more aggressive
early intervention should be undertaken in order to ensure an AVF remains patent, and to
limit CVC placement.
Farber et al [51] assessed early thrombosis in AVFs in over 600 patients. They found
female gender, smaller arterial diameter, draining vein diameter of 2 to 3 mm, and use
of the medicine protamine to be risk-factors for early thrombosis. Forearm AVF place-
ment was shown to increase the risk of early thrombosis when compared to upper arm
AVF placement, possibly due to the smaller size of the radial artery in these AVFs. Dia-
betes was found to be inversely associated with early thrombosis, perhaps due to selection
biases for AVF creation in diabetic patients.
Weale et al [182] studied BC and RC-AVFs in over 700 patients, splitting them into
age groups of < 65, 65 - 79, and ≥ 80. They found no difference in the patency of either
type of AVF between the age groups, but note female gender as a risk-factor for non-
maturation of RC-AVFs. Miller et al (2003) [112] found female gender to be a risk-factor
for AVF failure, despite the use of US mapping to identify suitably sized vessels. Vessel
diameters were not found to be the reason for AVF failure in this group, as the diameters
of successful and unsuccessful AVFs did not significantly differ.
Two meta-analysis have confirmed the negative effect of old-age on AVF patency. In
2007, Lazarides et al found a 50% increased risk of RC-AVF failure in elderly patients
(most commonly > 65 years old). BC-AVFs were found to have a 12% higher patency
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in this group, suggesting this may be a more appropriate choice in elderly patients, when
salvaging of access sites is less important due to lower life expectancy. Almasri et al,
in 2016, conducted another meta-review including all VA types. Again, they found that
female gender, old-age (> 65) and diabetes were related to decreased AVF patency at 2
years.
If patients are screened for risk-factors prior to AVF creation, clinicians can make an
informed decision as to the best option for vascular access, and patient’s can become more
aware to the risks of AVF creation, and the likelihood of failure.
1.7.2 Novel pre-operative markers for AVF failure
Despite pre-operative US assessment, and the detection of risk-factors, AVF failure is still
high. This has led to researchers attempting to identify additional risk-factors for AVF
failure [106]. Suggested markers are typically physiological assessments of the vascula-
ture, or biomarkers indicative of reduced endothelial function.
Arterial Stiffness
Arterial stiffness (AS) is an age related structural change that occurs in the cardiovascular
system, leading to the stiffening and thickening of major arteries [11]. AS increases with
age, and in the aorta stiffening is associated with fracture of elastin and an increase in col-
lagen, increased arterial wall thickness, and calcium deposits [30]. Other vessels change
differently with age and peripheral vessels have been observed to stiffen less than the
aorta [114, 13]. Increased arterial stiffness limits the ability of the arteries to accommo-
date blood ejected from the heart. Due to the physics of waves, stiffer materials propagate
waves with a higher velocity. This is the most recognisable feature of AS, and forms
the basis for its measurements with techniques such as pulse wave velocity. A secondary
consideration of AS is the resulting impedance matching between different arterial seg-
ments [35]. This can result in increased propagation of pulse energy throughout the entire
arterial tree.
Increased AS has two important implications, caused by the increased pulse wave
velocity, and impedance matching. The increased velocity of the reflected waves causes
their earlier return to the heart. Earlier arrival of these reflected waves can interfere with
and increase the workload of the heart, particularly if they arrive during ejection release
[35]. Conversely, impedance matching can reduce the amplitude of pulse reflections,
38
meaning that more pulse energy can be delivered to more distal points in the arterial tree.
Waves can then propagate into the smaller vascular beds of the organs, and the increased
energy transfer here can result in targeted organ damage [113].
AS increases with age, and is increased in diseases such as hypertension, diabetes
mellitus, hypercholesterolemia [139], and is an independent predictor of cardiovascular
mortality in patients with ESRD [33]. Patients with ESRD are observed to have increased
AS, when compared to hypertensive patients with identical arterial pressures and con-
trols, suggesting kidney failure can have a significant effect on the composition of the
arteries [119]. Pulse-wave velocity (PWV) is the gold-standard method for assessing ar-
terial stiffness, and involves tracking the pressure pulse through at least two points in the
cardiovascular system. Using pressure sensors, the speed of the pulse is indexed by mea-
suring the time taken for the pulse to propagate between two points in the cardiovascular
tree. Stiffer arteries will permit faster propagation of the pressure pulse, which is detected
as an increased pulse wave velocity.
AS has been identified as a possible biomarker of AVF failure [106]. A study by
Korsheed et al [80] revealed that AVF creation had the effect of reducing global values
of AS, diastolic and systolic blood pressure, and that patients with a successful AVF
showed a decrease in PWV after two weeks. In 2010 a study by Kheda et al [74] linked
high arterial stiffness to AVF stenosis, but noted that adequate blood flow was still seen
regularly in their group of 32 patients despite high stiffness. A 2016 study of 59 patients
concluded that AS (measured by PWV) was not predicative of failure to mature [103], but
recommended further research.
Endothelial Function
Markers of endothelial function have potential use in predicting AVF outcomes. The com-
mon US based examination of endothelial function, FMD, has been assessed prior to AVF
creation [45, 128], with mixed outcomes. Owens et al [128] found endothelial function
to correlate well with the degree of arterial remodelling observed in a small cohort study,
demonstrating that arterial remodeling in AVFs is an endothelial process. However, this
study did not assess links to the clinical outcome of the AVF, so its predictive value is
unknown. Dember et al [45] assessed endothelial function using FMD in 602 patients
awaiting AVF creation, and found that it varies to a large extent in this group of patients.
However, the AVF outcome of these patients was not reported. Using a different tech-
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nique, peripheral artery tonometry (PAT), MacRae et al [101] assessed the endothelial
function of patients awaiting AVF creation. Patients with higher PAT values had a higher
chance of reaching AVF maturation than those with lower values in a small cohort of 28
patients. Larger studies of suitable design are needed to assess if endothelial function
testing can be used as a marker for AVF outcomes.
Inflammatory Markers
Patients receiving RRT routinely have bloods taken for analysis to track progression of the
disease, and this opens an accessible pathway for longitudinal studies of chemicals and
proteins in the blood. Certain markers such as C-reactive protein (CRP) and albumin have
been well-studied in realtion to AVFs, likely due to the abundance and ease of measure-
ment in many institutions. CRP is known to correlate with endothelial dysfunction [187],
so an increased baseline value, as experienced by ESRD patients, could hinder arterial
dilation. Correlations between CRP and AVF failure have been observed in a number of
studies [188, 111, 38].
Other blood-borne markers are of interest: Anti-symmetric dimethyrarginie (ADMA)
has a known negative effect on endothelial function through the impairment of nitric oxide
production [160]. Meng et al [109] demonstrated elevated ADMA in patients on HD. A
study by Wu et al [184] demonstrated a relationship between increased ADMA and AVF
re-stesnosis after intervention. In 2012 a small study of 68 patients [22] identified that the
red blood cell distribution width was predicative of reduced patency after 2 years, whilst
finding that CRP levels were not. However, a 2016 meta-analysis [118] determined that
zero blood-borne markers were significantly related to AVF outcome. The authors state
that this is primarily due to hetrogeneity in the assessed studies; different outcomes were
analysed, blood measurements were taken at different time-points, and different statistical
analyses were used.
1.7.3 Alternatives for pre-operative assessment
New methods of assessing arterial stiffness or compliance via US have recently emerged,
including shear wave elastography (SWE), and strain imaging.
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Shear Wave Elastography
Shear wave elastography uses shear waves generated from focussed US to map tissue
stiffness. A shear wave causes particles in a medium to oscillate in a transverse direction
to the wave motion. The shear wave propagation velocity (SWV), in tissue of density ρ,
is related to Young’s Modulus (Y):
Y = 3× ρ× SWV 2 (1.4)
This equation relies on various mechanical assumptions, such as elastically homo-
geneous materials, finite in space, which are biologically unrealistic [110]. By tracking
the motion of these waves through a tissue sample using high frame-rate techniques it is
possible to estimate the velocity, and obtain an indirect measurement of tissue stiffness
(see figure 1.20). Commercially available US SWE packages typically measure the mean
value of the shear wave velocity inside a user defined ROI.
Shear wave elastography has found widespread clinical application in breast, liver,
thyroid and lymph node imaging [162, 120, 52, 92]. Recently, a number of groups have
used shear wave elastography to investigate the cardiovascular system. Couade et al [41]
were the first to assess local arterial stiffness using shear wave elastography, in one healthy
volunteer. They observed that the stiffness of the carotid artery varied throughout the car-
diac cycle, increasing in late systole. Li et al [95] used shear wave elastography to assess
the carotid artery in patients with ischemic stroke. The group assessed the longitudinal
stiffness of the carotid, and found that this measurement correlated well with PWV (r =
0.7). They also identified increased arterial stiffness in the group with ischemic stroke
using both techniques, when compared to age and sex-matched controls. Ramnarine et al
[144] used the technique to identify increased Young’s modulus in carotid plaques associ-
ated with neurological symptoms. It is possible that differences in the shear wave velocity
could identify patients at increased-risk of AVF failure.
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Figure 1.20: Shear wave velocity map of a brachial artery
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Strain Imaging
Strain imaging is a technique primarily used to in the assessment of myocardial damage
after infarction, and involves quantifying tissue deformities, typically via US. Strain (ε)
can be described as a deformation, and expressed as a relative change in length (L) or
volume due to some force :
ε =
∆L
L0
(1.5)
Strain is expressed as a percentage, with positive values describing thickening and nega-
tive values describing stretching.
The rate at which strain occurs, the strain rate, can be calculated according to:.
∆ε
∆t
=
∆V
L0
(1.6)
Where ∆V is the velocity gradient in the sample studied.
Strain imaging is possible in 2D due to the advent of speckle tracking. The speckle on
an US B-mode image is the result of scattered waves from rough structures smaller than
the US wavelength. These scattered waves can then interfere, causing constructive peaks
(bright dots) and destructive troughs (dark dots) in the resultant signal, known as speckle.
The speckle remains stable spatially throughout frames during an US scan [89]. Complex
algorithms allow tracking of the speckle from frame to frame. Geometric differences in
the speckle between frames allows for measurement of displacement, and knowledge of
the frame rate allows calculation of the velocity. In this way, the motion of the speckle
represents the motion of the tissue. Typically, a contour is placed on a tissue of inter-
est on a B-mode ultrasound image, and this contour tracks tissue movement through the
speckle tracking technique. The strain and strain rate are calculated through the measured
displacement and velocity of the contour.
Multiple groups have adapted the speckle-tracking packages to analyse other parts of
the cardiovascular system such as the aorta and carotid [168, 77, 100, 8], finding good
correlations (r = -0.7) with markers of arterial stiffness [138, 77]. Healthy subjects have
been shown to produce regular and periodic profiles of wall motion when assessed with
strain imaging [185, 77]. Ma et al [100] observed that the carotid of patients with pre-
eclampsia produce non-uniform velocity profiles and Cho et al [36] had similar findings
in patients with Takayasu’s arteritis. This suggests that in certain groups of patients, the
vessel movement is not synchronised.
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Multiple strain imaging platforms exist, developed by various manufacturers. The
Velocity Vector Imaging (VVI) package by Siemens, is “an advanced 2D quantitative
tool for assessment of global and regional myocardial muscle and motion mechanics”.
VVI can analyse the strain, strain rate, velocity and displacement of imaged tissue, and
can graphically display tissue movement patterns. It is possible that differences in VVI
measurements of strain or strain rate could identify patients at increased-risk of AVF
failure.
Other US-based Methods
Other US-based assessments may have potential uses in predicting AVF outcomes. A
study by Ku et al [84] used US to assess the intima medial thickness (IMT) of the ra-
dial artery prior to AVF creation. They found increased IMT to have a negative effect on
maturation, but did not elude to reasons this could cause failure, other than poor vascu-
lature. IMT could benefit from further study, and perhaps increased IMT could act as a
risk-factor for AVF failure.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) has been previously explored as a potential modality
for the pre-operative assessment of patient’s vessels prior to AVF creation. MRI is an
attractive diagnostic tool as it can provide excellent angiographic images, with or without
contrast agent [47, 57]. Specifically, Planken et al [136] have shown contrast-enhanced
(CE) MRI as an accurate modality for providing pre-operative measures of forearm ves-
sel and upper arm venous diameters in patients indicated for AVF creation. In this study,
agreement was seen between diameter measurements obtained from US and CE-MRI.
Results taken intra-operatively showed a deviation from those obtained by US, but in
agreement with CE-MRI. The results on US showed a larger standard deviation, suggest-
ing that the US method used was less precise. A further study by Planken et al [137] found
CE-MRI to be superior to US in detecting venous pathologies in 73 patients prior to AVF
creation, with the most frequent being upper arm cephalic vein occlusion. CE-MRI was
able to identify pathologies missed by US responsible for future AVF dysfunction and for
AVF ‘failure to mature’ in 33% of the study population with AVF dysfucntion, however
clarification is not given as to where these mismatches occurred. The authors remark that
in the remaining 67% of failures, venous stenosis was the main cause, and these stenosis
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developed rapidly after AVF creation.
However, commonly used contrast in MR imaging is currently contraindicated for
patients with renal failure, due to associations with a disease called nephrogenic sys-
temic fibrosis [88]. Non-contrast enhanced (NCE) or alternate contrast MRI methods are
emerging as a research tool for patient’s undergoing AVF creation. Pre-operatively, few
studies have used NCE-MRI to image the vessels of patients indicated for AVF creation.
Menegazzo et al (1998) [108] compared Time of Flight (ToF) imaging with venography
to assess the depiction of veinous diameters prior to AVF creation. The found a greater
correlation between the ToF measurements and surgical findings than venography, but
venography is less commonly used compared to US. In 2012, a study by Bode et al [21]
used CE-MRI and a NCE balanced turbo field echo sequence to detect stenosis prior
to AVF creation. The NCE-MRI detected 66% of (non-significant) stenosis found on
CE-MRI, but importantly these were not seen on previous US imaging. More recently,
NCE-MRI sequences, such as the Multi Echo Data Image Combination (MEDIC) [78],
along with increases in magnetic field strength, have shown promising results when used
to image the lower limbs, suggesting that non-contrast MRI may once again be considered
a suitable choice for pre-surgical mapping and surveillance of AVFs.
Figure 1.21: In recent years a growing trend of NCE and alternate contrast material being used in studies
of VA is observed, proceeded by the growth and fall of Gd based contrast pre-NSF. From work presented at
UKRC, 2017. NCE: non-contrast enhanced, Gd: Gadolinium, Fe: Iron
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1.8 Aims
The main aim of this thesis is to assess whether existing and potential risk-factors for AVF
failure are related to the AVF outcome in a local cohort. A secondary aim is to address
a gap in the CFD literature regarding reproducibility of CFD simulations from different
MRI sequences.
As such, this thesis can be separated into the introduction, and three main research
questions.
• Chapter 1 introduces the AVF, discusses attempts to identify risk-factors for AVF
failure, and includes computational efforts to understand the effect of wall-shear
stress on AVF stenosis. Multiple known risk factors such as diabetes, age and vessel
diameters are discussed, and potential markers of failure introduced.
• Chapter 2 aims to answer the question are known risk-factors and serological mark-
ers predicative of AVF outcome? Previous research involving identification of risk-
factors for AVF failure have been conducted in different settings, with differing
patient demographics. It is possible that risk-factors identified in studies conducted
in the USA for example may not be applicable to UK, or more specifically Scottish
populations. Knowledge of which patients are likely to have an unsuccessful fistula
can lead to choices of an alternative vascular access, such as an AVG placement,
identification of patients who may benefit the most from US-based surveillance,
or to better patient counseling towards the risks of AVF creation and subsequent
failure. This section uses health informatics and machine learning methods to de-
termine if a link exists between known risk-factors such as diabetes, age and gender,
and pre-operative blood measurements, and the outcome of a patients AVF, in a sin-
gle centre, retrospective study;
• Chapter 3 aims to answer the question are US markers of arterial elasticity and
strain risk-factors for AVF failure? This uses modern ultrasound technologies
(shear wave elastography and velocity vector imaging) to determine if pre-operative
measurements arterial elasticity and strain are related to the outcome of a patient’s
AVF;
• Chapter 4 aims to answer the question is 3T MRI useful as part of the pre and post-
operative workup for patients indicated for AVF creation? A major draw-back of
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US imaging is its inability to image the central veins. MRI imaging offers superior
central vein depiction, and could be used to screen for central vein pathology prior
to AVF creation. This study involves piloting modern MRI sequences in a small
prospective study to determine if any benefit could be gained from this underutilized
imaging modality, in order to pave the way for central vein study. Using the same
images, chapter 5 compares CFD simulations from the two different MRI sequences
used, and in a series of phantoms in order to determine if similar CFD results are
obtained regardless of imaging sequence.
Limitations of the research are described in each chapter. Chapter 6 concludes the
work, provides impact and suggestions for future work following on from this research.
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Chapter 2
Blood-Borne and Demographic
Risk-Factors
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2.1 Introduction
Biomarkers are widely studied in the field of nephrology. Certain biochemical mark-
ers are associated with increased mortality in ESRD patients, such as CRP, albumin and
interleukin-6 [126]. These markers are also associated with adverse cardiovascular out-
comes [148, 34]. A small number of studies have examined the association between
blood-serum markers and AVF failure. Low serum albumin has been observed in patients
with primary AVF-failure [2], and in patients with a high-risk (three or more dysfunction
events) of VA failure when compared to patients with a lower-risk [32]. Further studies
have observed a combined increase in CRP and decrease in serum albumin in patients
with AVF failure [22, 72], however, a number of studies have found CRP and albumin to
be unrelated to AVF outcome [17, 28, 76].
Additional markers have been studied, and have been found to have an effect on AVF
patency. Increased levels of ADMA taken at the time of angioplasty, have been correlated
with re-stenosis of AVFs after intervention [184] (see section 1.7). High levels of free P-
cresol A, which is possibly associated with increased oxidative stress and inflammation,
measured after AVF creation and during HD treatment have been linked to lower levels
of AVF patency [32]. A separate study observed that high levels of fibrinogen, a blood
clotting protein, at the time of AVF creation were linked with increased failure rates [164].
A meta-analysis of blood markers including albumin and CRP, found that none were
associated with all-cause AVF failure [118]. The authors of this review suggest that this is
due to heterogeneity of failure definitions and the time-point of blood measurements. Of
the 12 studies they assessed, most included under 100 patients, and only three assessed
marker values prior to AVF creation, making conclusions about the predictive power of
markers difficult. Currently, there exists no pre-operative blood-borne risk-factor for AVF
failure, perhaps due to heterogeneity in study populations. A local study allows determi-
nation if risk-factors which have commonly been identified in large american studies can
also be applied to local UK cohorts, which can vary demographically between cities. If
a marker of AVF failure can be identified, patients could be better counselled to the risks
of AVF failure, or ultimately an alternative choice of vascular access with reduced risk of
failure could be recommended for the patient.
This chapter aims to answer the question: Are known risk-factors and serological
markers related to AVF failure in a single centre retrospective study?. This chapter also
provides the population overview of the ESRD cohort in Ninewells hospital, the main
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study cohort of this thesis, and describes their AVF patency outcomes. This institution
performs US based surveillance, with patients scheduled for follow up at six weeks, three
months, six months and one-year post AVF creation, allowing detailed tracking of a pa-
tients AVF. Data was linked from multiple sources to create accurate timelines of each
AVF, including analysis of dysfunction events. Health informatics was used to create a
detailed picture of each individual patient, and logistic regression to identify factors as-
sociated with AVF failure. Finally, an algorithmic approach is used to demonstrate the
classification potential of markers identified in this cohort.
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2.2 Methods
2.2.1 Patients
A retrospective review was performed on all patients undergoing RRT via HD with a pri-
mary AVF at our institution. Patients were identified by their presence on the Scottish
SRR. Data analysis was performed on demographic factors, and on routine blood bio-
chemistry measurements taken during the work-up six-months prior to RRT, and follow-
up to RRT for each patient.
2.2.2 Inclusion and Exclusion Criteria
All patients who were placed on the SRR between October 2012 and January 2017, and
were known to have a primary autologous AVF created at this institution were included.
This date range was chosen as confidence on data accuracy prior to 2012 was limited.
All patients were on a routine US-based surveillance program. Only the first AVF was
considered, patients subsequent AVFs were not included in the analysis. Patients who
were on peritoneal-dialysis at the time of AVF creation were excluded from the study.
2.2.3 Data Collection
Caldicott approval from the local Ethics Service was obtained, anonymised patient data
(including biochemistry, demographic, surgery, diabetes) was supplied by the universi-
ties Health Informatics Centre (HIC, Farr Institute) in .csv format. AVF creation data
was manually collected from vascular laboratory databases. Data on AVF surgical in-
terventions was manually collected from radiological records, and vascular laboratory
databases. All manually collected datasets were then passed to, and anonymised by HIC.
For each patient, a timeline was created including date and type of AVF creation, date
of starting HD or RRT, and the date of any surgical interventions, AVF related events or
death. Timeline creation was performed using Python 2.7. Biochemistry measurements
were linked to the patient’s timeline, and recorded as a 6-month mean prior to AVF cre-
ation. Biochemistry results were available for % saturation of transferrin, HbA1C, albu-
min, aldosterone, alkaline phosphatase, alanine transferrase, aluminium, amylase, Beta-
microglobulin, bence jones protein, bicarbonate, bilirubins, c-peptide, c-reactive protein,
caeruloplasmin, calcium, chloride, cortisol, creatinine, digoxin, ferritin, glucose, hap-
toglobin, hdl-cholesterol, iron, lactate, ldl-cholesterol, magnesium, parathyroid hormone,
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phosphate, potassium, procalcitonon, prolactin, total cholesterol, transferrin and urea. If
25 % of the cases lacked a certain blood measurement for analysis it was excluded from
analysis.
2.2.4 Study Outcomes and Definitions
The aim of this study was to determine if routine blood measurements taken as part of
a patients work-up to RRT could predict the outcome of AVF creation at 1-year. The
“high-risk” group was defined as including those who had at least 1 intervention event or
AVF abandonment within 1-year of creation, with 1 year chosen to match the commonly
reported 1 year patency rates. Dysfunction events were identified retrospectively from
vascular laboratory and radiological intervention databases. Those without an event or
failure at 1-year were included in the “low-risk” group.
The predictive power of various blood markers, and various categorical variables such
as sex, diabetes status, and AVF site were analysed. The type of vascular access used prior
to AVF creation, and the time from commencing RRT to AVF creation was recorded.
For patency analysis, primary patency was defined as the “intervention free access
survival” or the interval from time of access placement to any intervention designed to
maintain or reestablish patency. Assisted primary patency was defined as “thrombosis-
free access survival” or the interval from time of access placement, including intervening
manipulations, to access thrombosis or abandonment (patients whose loss of primary pa-
tency resulted in AVF abandonment were censored from primary assisted patency analy-
sis).
2.2.5 Ultrasound Assessment
All patients within this study had a pre-operative ultrasound assessment prior to fistula
creation and then were subsequently placed on a routine surveillance programme. Using
a high frequency 14MHz transducer (Tx) the veins and arteries of the arms were assessed
both in longitudinal and transverse plane.
Pre-operatively, the arteries were assessed for patency and phasicity, with only tripha-
sic or biphasic (normal) waveforms as acceptable criteria. The diameter was also recorded
with a minimum acceptable diameter of 2mm. The veins were assessed for patency, diam-
eter, and uniformity, with a reduction in diameter to less than 3mm indicative of possible
stenosis.
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Post operatively patients were placed on a routine surveillance programme. When
a significant stenosis was identified the cases were discussed within a multi-disciplinary
meeting and patients were referred for intervention.
2.2.6 Statistical Analysis
All analysis was performed using Python 2.7 and R. Biochemistry data was recorded as
mean± standard deviation. Continuous data was graphically assessed for normality. Dif-
ferences between categorical and continuous variables in the high and low-risk groups
were assessed using chi-squared, Student’s t, and Mann-Whitney U tests, and are pre-
sented in section 2.3.1. Sub-group analysis was performed on patients with and without
dialysis history prior to AVF creation.
General Linear Models (GLM) of the binomial family (i.e. logistic regression) were
created in RStudio (RStudio Inc, USA) to assess the predictive power of variables, with
inclusion in the high-risk group as the dependent variable. Variables were placed in the
model owing to identification in the literature, or if a statistically significant difference (p
< 0.10) was identified between the high and low-risk group according to statistical tests
(chi-squared, Student’s t, Mann-Whitney U).
As per SAMPL guidelines [87], model accuracy, and variable correlations were as-
sessed. Predictive accuracy of the models was assessed using McFadden’s Pseudo R-
squared [67]. Goodness-of-fit of the predicted distributions was assessed using Pearson’s
Chi-squared statistic [65].
As a form of verification, a K-Nearest Neighbors (KNN) classification machine learn-
ing algorithm was used to assess the predictive power of any markers identified. This
model was chosen under the hypothesis that patients with similar blood values would
have similar outcomes. Data was scaled and then split into training and test-data, using
Python and scikit-learn [132], using the same outcome as the GLM. The RF model was
trained on the training set and used to predict the outcome of patients in the test set. Grid-
ding methods were used to hyper-tune the RF model. Results were interpreted using a
confusion matrix to show true/false positives and negatives of the model.
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2.3 Results
920 patients were initially identified by HIC, but 720 were excluded as their entry on the
SRR did not fall within the study period (2012 - 2017). 210 patients were identified, all
on RRT at our institution, and having been placed on the SRR during the study period.
72 patients were excluded, due to lacking AVF creation data (n = 59), or first modality
of RRT was not HD (n = 13). One patient was removed as AVF was created as part of
a work-up for a Whipples procedure. 137 patients remained, all having a primary AVF
created within the study period. The exclusions process is visualised in figure 2.1.
Figure 2.1: Flow chart showing patient inclusion and exclusion
The mean age of the patients was 66.7 ± 13 years, and 58 % were male. The most
common cause of ESRD was diabetes (27%), followed by vascular disease and hyper-
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tension (13%). Other causes of ESRD included kidney tumours, traumatic injury and
polycystic kidney disease. All patients had at least one AVF created for HD. Full demo-
graphic and blood measurement data can be seen in table 2.1.
Total (n = 137) High risk (n = 45) Low risk (n = 92) p-value
Age (years) 66.7 ± 14.0 66.3 ± 12.2 66.9 ± 14.8 0.32
Sex male (count) 80 26 54 0.9
Prev. HD (count) 49 21 28 0.06
Diabetes (type 1/2) ( count) 19 / 44 4 / 18 15 / 26 0.33
% Satn. Transferrin 21.0 ± 6.9 20.0 ± 6.9 21.5 ± 6.8 0.12
Albumin (g / L) 32.9 ± 6.7 31.0 ± 6.5 33.7 ± 6.7 0.007
ALT (U / L) 21.6 ± 10.7 21.1 ± 9.9 21.8 ± 11.1 0.26
Bicarbonate (mmol / L) 23.8 ± 3.3 24.5 ± 3.3 23.2 ± 3.2 0.027
Bilirubins (umol / L) 5.7 ± 2.2 5.8 ± 2.3 5.6 ± 2.2 0.29
C-reactive protein (mg / L) 31.7 ± 35.5 40.7 ± 36.4 27.2 ± 34.4 0.016
Creatinine (umol / L) 388.6 ± 106.2 397.3 ± 118.1 384.3 ± 100.2 0.31
Ferritin (ug / L) 312.0 ± 246.3 257.6 ± 185.5 340.5 ± 269.6 0.036
Iron (umol / L) 10.5 ± 3.6 10.2 ± 4.3 10.7 ± 3.3 0.1
Phosphate (mmol / L) 1.5 ± 0.3 1.6 ± 0.3 1.5 ± 0.3 0.08
Potassium (mmol / L) 4.8 ± 0.5 4.7 ± 0.5 4.8 ± 0.5 0.23
Sodium (mmol / L) 139.7 ± 2.7 139.4 ± 2.8 139.8 ± 2.7 0.26
Transferrin (g / L) 2.0 ± 0.4 2.0 ± 0.4 2.0 ± 0.3 0.43
Urea (mmol / L) 20.0 ± 5.1 20.3 ± 4.9 19.8 ± 5.3 0.17
Table 2.1: Demographic and biochemical results from the study population
Over the full study period, a total of 57 patients underwent at least one AVF interven-
tion or failure event. 45 patients had an intervention to maintain patency, primarily due to
stenosis (42 cases), and three cases of stenting a pseudo-aneurysm. 12 patients had their
AVF abandoned without a prior intervention, primarily due to occlusion/thrombosis (nine
cases), one failure to mature, one ligation of an aneurysmal fistula, and one unknown
cause. A further 13 patients who underwent at least one intervention to maintain patency,
ultimately underwent AVF abandonment. This was primarily due to thrombosis/occlusion
(nine cases, five of which caused by a failed angioplasty), followed by stenosis leading to
reduced flow (three cases) and one unknown cause. 11 patients died within one-year of
AVF creation, with a patent AVF.
For blood marker analysis, the high risk group included 45 patients who underwent
intervention or AVF abandonment within one year. The remaining patients were placed
in the low-risk group. Following earlier definitions, primary patency at one year was ap-
proximately 67%. At one year, primary assisted patency was approximately 91%. Figure
2.2 demonstrates primary patency and primary assisted patency in this cohort.
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Figure 2.2: Primary and primary assisted AVF patency of the whole study cohort. Each step down represents
one loss of primary or primary assisted patency in the whole group.
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2.3.1 Group Analysis
Full biochemistry results for the high and low-risk groups can be seen in table 2.1. When
comparing the pre-operative biochemistry results, values for albumin, bicarbonate, CRP,
and ferritin were found to differ at a statistically significant level between the high and
low-risk groups (all p < 0.05). Differences in phosphate levels were approaching signif-
icance (p = 0.08). Differences between the high and low-risk groups for these markers
can be seen in figure 2.3. History of previous haemodialysis was more common in the
high-risk group (p = 0.06). Percentage saturation of transferrin (SATN), and iron showed
the highest correlation of 0.7 (see figure 2.4). Percentage saturation of transferrin was
removed from further analysis at random as neither removal had a large effect on the final
model.
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Figure 2.3: Boxplots of statistically different blood measurements between the high and low-risk groups. A
: Albumin, B : Bicarbonate, C : C-Reactive Protein, D : Ferritin, E : Phosphate
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Figure 2.4: Heatmap of correlations between variables, with bolder colour indicating a higher value of
Pearson’s R statistic between pairs of variables as indicated on the x and y axes. A high correlation was
observed between iron and % saturation of transferrin, as indicated by the bold colouring.
Sub-group analysis revealed differences in biochemistry measurements between pa-
tients with and without previous HD. These differences can be seen in table 2.2 and figure
2.5. These differences are likely caused by the different uremic state of these patients, and
certain treatments in HD patients such as iron infusions, and the presence of bicarbonate
products in the dialysate.
A logistic regression model was used to assess if variables were statistically asso-
ciated to the classification of the patient as high or low-risk, using variables identified
previously, controlled for known risk-factors. The model suggests that decreased pre-
operative ferritin, and increased phosphate increases the risk of a negative AVF outcome
at a statistically significant level. Full results from the binomial GLM can be seen in table
2.3. Pearson’s Chi-square statistic was large for this model (p << 0.05).
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Prev. HD No prev. HD
Albumin (g / L) 30.5 ± 6.2 34.5 ± 6.5
Bicarbonate (umol L) 24.7 ± 3.5 23.2 ± 3.0
C-reactive protein(mg / L) 42.1 ± 40.3 23.2 ± 28.5
Iron (umol L) 9.4 ± 2.9 11.4 ± 3.7
Transferrin (g / L) 1.9 ± 0.3 2.1 ± 0.3
Urea (mmol / L) 18.8 ± 5.4 20.9 ± 4.7
Table 2.2: Variables which showed significant differences between the group with previous dialysis history,
and no previous dialysis history. All p < 0.05. Variables not included in this table, but present in table 2.1
were not statistically significant between the groups
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Figure 2.5: Boxplots of statistically different blood measurements between the prev. HD and no prev. HD
groups. A : Albumin, B : Bicarbonate, C : C-Reactive Protein, D : Iron, E : Transferrin, F : Urea
A KNN algorithm was used to predict the outcome of 35 patients in a random test
set taken from the full cohort of 137 patients, after training on a dataset including AVF
outcome, ferritin, phosphate and diabetes. Optimised model parameters were: neighbors
= 4, weighting = distance, train-test split = 0.25 stratified to the outcome. The accuracy
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Coefficient p-value
Age -0.009 0.66
Sex male -0.6 0.22
Upper-arm AVF 0.11 0.84
Prev. HD 0.35 0.52
Diabetes (type 1 / 2) -1.99 / 0.8 0.07 / 0.12
Albumin -0.08 0.09
Bicarbonate 0.15 0.08
Bilirubins 0.2 0.06
C-reactive protein 0.009 0.21
Ferritin -0.004 0.003
Phosphate 1.88 0.03
Pseudo R2 0.33
Chi-squared 105.6
Table 2.3: Output from logistic regression model, modeling patient outcome as high or low-risk
of predictions was 77 %. The model correctly predicted the outcome of 27 patients,
including 20 true negatives and 7 true positives, 4 false positives and 4 false negatives.
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2.4 Discussion
A retrospective study of primary-AVF outcome at one-year, in a cohort of patients at this
institution was performed. Analysis of blood-serum markers and demographic factors,
and their relations to the outcome of AVF creation was undertaken. Health informatics
methods allowed creation of a detailed timeline for each patients AVF. This included
detailed US-based surveillance data, allowing identification of the specific causes of AVF-
failure. Retrospective studies often suffer from limitations such as incomplete data, and
inaccuracies.
AVF failure is the Achilles heel of successful HD treatment. Once matured, AVFs
offer increased long-term patency, reduced infection rates and likelihood of thrombosis
or stenosis. However, AVF failure is a significant source of morbidity in the dialysis
population, with associated costs and disruption to a patient’s life. In our institution, we
have observed a loss of primary patency in 33% of patients within one year. If biomarkers
can be identified that can independently or cumulatively predict risk for AVF failure prior
to creation, a patient could be selected for more rigorous surveillance, an alternate VA, or
counseling towards the risk of AVF failure.
During statistical analysis, adherence was payed to reporting guidelines defined by
SAMPL [87]. This included assessing model fits and attempting to validate the model.
Logistic regression analysis suggested lower pre-surgical ferritin and increased phosphate
levels can increase the risk of all-cause AVF-failure within one year. A large chi-square
statistic suggested that the predicted distribution of high-risk patients in the logistic re-
gression models did not fit the expected distribution, indicating poor model fit. Along
with the small sample size, this causes us to question the power of the markers (phos-
phate and ferritin) as independent risk-factors of AVF failure. Although only consisting
of 137 patients, this is an improvement over previous attempts, which have primarily
been in cohorts smaller than 100 [118]. Bivariate analysis showed a difference in al-
bumin measurements between the two groups, however this was likely explained by the
previous dialysis history of the patients. In agreement with multiple previous studies
[17, 28, 76, 118], logistic regression analsysis demonstrated no relation between AVF
outcome and the inflammatory markers CRP and albumin.
As a form of model verification, a KNN algorithm was used to classify patients as
high or low risk, based on their ferritin, phosphate and diabetes values prior to AVF cre-
ation. This model performed relatively well, successfully classifying correctly 77% of
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patients in the test-set. Verification of this algorithm would be required in other cohorts
before being fully accepted, however this represents a step towards the health-informatics
approach desired in many institutions. Further prospective studies of these markers are
required to determine the power of these predictions, and to determine if cut-off levels
exist which can predict the outcome of the AVF.
This study includes some limitations, primarily a small sample size. Measurements of
vessel diameter were not included in this analysis. If one takes the view that AVF failure
is a multi-factorial problem, known risk-factors such as vessel diameter and presence of
calcium in the vessels should be included in modeling. This study was not designed
to assess the multi-factorial view and would have lacked statistical power for such an
analysis. It is noted that none of the markers identified during the exploratory ANOVA
testing would have been recorded as significant if multiple-hypothesis correcting had been
applied. However, as the goal of the study was not to compare means between the groups,
their inclusion in the model is justified.
Patients with ESRD can have fluctuating concentrations of proteins in the blood, due
to the nature of the disease (see figure 2.6). This adds a source of noise into the mea-
surements assessed in this study. In attempt to filter this noise, averaging over a 6-month
timeframe prior to AVF creation was performed, with six-months chosen as this is within
the planning period recommended by K-DOQI guidelines.
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Figure 2.6: CRP measurements over time for four randomly selected patients in the study cohort, showing
the varying nature of concentration in the blood. Due to this, an average was taken over the six months prior
to AVF creation to reduce the apparent noise in the measurement.
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Primary patency at one-year was approximately 67%. This is in agreement with lit-
erature values of 1-year primary patency [3, 90], and provides the most recent record of
primary AVF patency for this institution. Primary assisted patency was very high at 1-
year, at approximately 91% , superior to values previously reported at 78% at 65 weeks
[7]. This institution performs a rigorous US based surveillance program with patients
scheduled for follow up at six weeks, three months, six months and one-year post AVF
creation. AVFs are intervened on early when stenoses are identified within the AVF and
compared with relative HD parameters before intervention is confirmed - typically only
if the stenosis is adversly affecting HD. It is however possible that this surveillance/in-
tervention practice reduces primary patency in exchange for increased primary assisted
patency, cost analysis would be required to determine if this is a justified tradeoff. In
light of this results, perhaps a more appropriate use of these serological markers may lie
in the differentiation of patients who require surveillance, and those who do not. Future
work could assess if ferritin and phosphate show high sensitivity towards those who do
not require intervention, thus acting as a screening tool for those who require surveillance
of their AVF. If successful, this would act to free up valuable time in vascular clinics.
It is possible that the observation is related to early signs of vascular calcification.
Phosphate and ferritin have both been observed to act in the vascular calcification path-
way, having inductive and inhibitive effects respectively [48, 99, 73, 190]. The combined
observation of increased phosphate and reduced ferritin is in line with results from Zarjou
et al [190], suggesting that ferritin inhibits calcification of smooth muscle cells, whilst
phosphate inhibits calcification through the up-regulation of bone lineage genes. Calcium
phosphate products have been identified in vascular samples of stenotic AVFs previously
[125]. Hyperphosphatemia has previously been identified in patients with AVF failure
[115, 116], suggesting a preventative treatment may be beneficial. There may be some
value in phosphate binding therapies in this population if further evidence is found.
In conclusion, low pre-operative ferritin and increased phosphate were found to be
related to AVF outcome, however a poor model fit and small cohort causes us to ques-
tion this relationship. Additional research into pre-operative ferritin and phosphate levels
may be beneficial, in particular to determine if cut-off levels exist which can aid in deci-
sion making. We have observed very low loss of primary assisted patency in this cohort,
demonstrating the benefits of rigorous US-based surveillance of a patient’s vascular ac-
cess. However, loss of primary patency remains comparable to literature reports.
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Chapter 3
Novel Pre-Operative Ultrasound Risk
Factors
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3.1 Introduction
Vessel diameter measurements from US remain the deciding factor for AVF creation, yet
failure rates remain high. US presents as a good modality for identification of additional
risk-factors due to its high specificity and sensitivity, as well as its availability, cost, and
current implementation in many vascular access clinics. Modern markers of arterial strain
and stiffness from US have proved useful in certain patient groups.
Using VVI, Ma et al [100] observed that the carotid artery of pregnant women with
pre-eclampsia produce irregular velocity profiles, and had lower strain values than nor-
motensive pregnant women. Cho et al [36] had similar findings regarding vessel wall
movement in patients with Takayasu’s arteritis. This suggests that in certain groups of
patients, the vessel movement is not synchronised. Studies have also recorded that strain
measurements from VVI correlate well with PWV [138, 77].
SWE has recently found use in the cardiovascular system. Li et al [94] imaged the
carotid of patients with ischemic stroke using SWE. Longitudinal measurements of SWE
correlated well with PWV (r = 0.7), and both modalities identified increased arterial stiff-
ness in the patient group when compared to healthy controls. Ramnarine [144] found
SWE to be a sensitive method for classifying carotid plaques that may be associated with
neurological symptoms.
This chapter aims to answer the research question: can US-based markers of strain
(e.g. VVI) and elasticity (e.g. SWE) act as pre-operative risk-factors for late AVF failure
or failure to mature? As part of work-up for AVF creation, all patients awaiting HD in
Ninewells undergo a pre-operative US assessment. This chapter focuses on the imple-
mentation of 2 new US methods, VVI and SWE. as part of the US based pre-operative
workup for AVF creation in a retrospective single centre study. SWE and VVI are first
demonstrated in a healthy cohort, before being compared to a patient group awaiting AVF
creation. The patients underwent follow-up for a period of up-to six months post-AVF
creation. These measurements were then statistically analysed in order to determine if
they could act as independent risk-factors for AVF-failure.
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3.2 Materials and Methods
3.2.1 Study Population and Ethical Approval
Patients were included in this study if they underwent a pre-operative US assessment for
AVF creation between November 1, 2016 and December 31, 2017.
From notes held in the vascular laboratory, patient age, BMI, and co-morbidities were
collected. Patient US images were acquired retrospectively from databases which hold
all images taken during the pre-operative assessment for AVF creation. Pre and post-
operative vessel diameters were obtained from routine B-mode US images. Brachial
artery SWE maps were obtained from the pre and post-operative assessment images.
Caldicott Guardian approval was granted for retrospective collection and analysis of
patient data, including images. A control group of healthy volunteers was recruited lo-
cally, and informed consent was granted from each individual. East of Scotland Research
Ethics Committee approval was granted for this study.
3.2.2 Volunteer Recruitment
Ethical approval was granted to recruit 40 healthy volunteers (HV) to take part in this
study. A4 posters (see figure 3.1) were placed around Ninewells hospital and medi-
cal school asking those interested in the study to contact the lead researcher by email.
Records of contact were maintained, and an anonymised key of participants was kept.
Volunteers were asked their age, BMI, current medical prescriptions, and the presence of
any disease such as diabetes or hypertension. Volunteers with conditions such as these
were disqualified from taking part.
3.2.3 Ultrasound Imaging
Initial set-up for US imaging was identical regardless of the assessment performed, for
both HV and patients. These scans were performed on an S2000 Ultrasound machine
(Siemens, Germany), with VVI and SWE software installed, by one of two operators.
The SWE software is compatible with the 9L4 range of transducers, thus a 9Mhz 9L4
transducer was used for all scans.
Three ECG patches were placed on the participant and connected to the US machine.
The red electrode was placed below the right clavicle, the yellow electrode below the left
clavicle, and the green electrode at the lower left ribcage.
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Figure 3.1: Poster advertising the study
All scans were conducted using a 9MHz linear transducer (Tx) in B-mode at a frame
rate of approx. 30 Hz. Participants were seated facing the operator and the arm of interest
extended over a pillow as in figure 3.2.
68
Figure 3.2: Participant positioning for US scanning
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3.2.4 VVI Imaging and Analysis
The Tx was used to locate a straight segment of the brachial artery proximal to the cubital
fossa in a cross-sectional view. Using the video capture function of the US machine, a
5 second cine loop was captured of the brachial artery in a cross-sectional view. The Tx
was then rotated through 90 degrees to obtain a longitudinal view of the artery with clear
intima. A 5 second cine loop was captured using the image capture button on the US
machine. All images were stored on the hard-drive of the US machine for analysis.
Image analysis was performed on the Siemens syngo Velocity Vector Imaging (VVI,
Siemens) package. Video series of the cross-sectional arterial view were selected and
loaded into the VVI package. Selecting the “Short Curve” option allowed placement of
a freehand region of interest (ROI) on the image. A freehand contour/ROI was placed
within the vessel wall of the artery using 6 points as in figure 3.3, between the intima and
vessel lumen.
2D velocity vectors corresponding to points on the contour are calculated via the
speckle tracking algorithm, and knowledge of the frame-rate. Geometric displacement
(∆L) of the speckle between frames allows knowledge of the displacement (d) of the tis-
sue, and the frame rate ( 1
∆t
) details the time taken for this movement, allowing calculation
of velocity (v) through the well known formula v = d
t
. Strain (ε) and strain rate can then
be calculated from from knowledge of the original speckle/contour geometry (L0):
ε =
∆L
L0
(3.1)
and
∆ε
∆t
=
∆v
L0
(3.2)
VVI output consists of graphs of velocity, strain, strain rate and displacement as a
function of time with the vessel wall was divided into six segments (see figure 3.4). The
amplitudes of peak velocity, strain, strain rate and displacement were taken for all six
segments, and then averaged over three cardiac cycles.
Once analysis of the cross-sectional arterial view was completed, the longitudinal
view was loaded into the VVI module. Using the “Long Curve” mode, an open rectangu-
lar ROI was placed along the wall of the artery using six points as in figure 3.5. The same
measurements were taken for longitudinal motion as before.
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Figure 3.3: short-axis ROI of brachial artery showing freehand ROI placement around the lumen of the
artery
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Figure 3.4: VVI output for two a healthy volunteer showing a periodic radial velocity profile
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Figure 3.5: long-axis ROI of brachial artery showing open box ROI placement within the intima of the
artery
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Figure 3.6: SWE map with ROI placement along the brachial artery wall, fully enclosing the intima layer.
This segment was not completely parallel to the transducer surface, resulting in varying depth of measure-
ment points.
3.2.5 SWE Imaging and Analysis
The Tx was used to locate a straight segment of the brachial artery proximal to the cubital
fossa in a cross-sectional view. The Tx was then rotated through 90 degrees to obtain a
longitudinal view of the brachial artery. A clear view of the intima layer of the artery was
desired. Vessel walls parallel to the Tx axis were prioritised over non-parallel regions to
avoid errors in shear wave velocity estimation due to varying depth.
The shear wave elastography function (Virtual Touch IQ) was selected on the machine,
and a rectangular shaped ROI was placed over the vessel wall. Upon user input, the Tx
produced a pulsed wave which generated a shear wave in the tissue. The shear wave
velocity was then displayed as a velocity map superimposed over the B-Mode image (see
figure 3.6). 8 square shaped ROIs were placed along the vessel wall enclosing the intima
as in figure 3.6, avoiding any areas of noise. All images were stored on the hard-drive of
the US machine for analysis.
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3.2.6 Statistical Analysis
Analysis was performed in Python version 2.7, using the “seaborn”, “pandas”, “scipy”
and “matplotlib” packages, and RStudio (RStudio inc, US). All data were collated as
mean ± standard deviation. Data distributions were assessed graphically. Differences in
data between volunteers and patients were assessed using the unpaired Student’s T-Test
and the Mann-Whitney U test. Categorical data was assessed using the chi-squared test.
Correlations between variables were assessed using Pearson’s r statistic.
15 HVs were selected at randomly to undergo identical tests by additional US operator.
Pearson’s r statistic was used to assess correlation between the users, and the intraclass
correlation coefficient (ICC) to assess agreement. Agreement between the operators was
assessed graphically, with an ordinary least squares (OLS) method used to fit a best-fit
line, according to the code below.
i m p o r t numpy as np
i m p o r t m a t p l o t l i b . p y p l o t a s p l t
d e f l e a s t s q l i n e ( x , y ) :
m = np . sum ( ( x − x . mean ( ) ) ∗ ( y − y . mean ( ) ) )
/ np . sum ( ( x − x . mean ( ) ) ∗ ∗ 2 )
c = y . mean ( ) − m∗x . mean ( )
x1 = np . l i n s p a c e ( min ( x ) , max ( x ) , l e n ( x ) )
f o r m u l a = m∗x1 + c
p r i n t ( ”m = ” , m)
p r i n t ( ” c = ” , c )
p l t . p l o t ( x1 , fo rmula , ”−−”, l a b e l = ” l i n e a r − f i t ” )
p l t . s c a t t e r ( x , y )
p l t . l e g e n d ( )
p l t . show ( )
20 HVs were selected at random to undergo assessment of both the left and right arm
to determine if the measurements were homogenous between the arms. Results from the
two arms were compared using a Wilcoxon signed-rank test, used to compare two related
samples, allowing determination if the two samples were taken from populations having
the same distribution.
Post-operatively, differences in the vasculature following AVF creation were assessed
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graphically and by using the paired students T-test. OLS regression models were used to
assess the influence of brachial artery elasticity or strain, pre-operative vessel diameters,
and demographic factors on arterial and venous diameter 6-weeks post AVF creation. A
logistic regression model was then used to assess the predictive power of US and demo-
graphic variables on the three-month outcome of the AVF. Three months was chosen due
to the timeframe of the PhD, and was realistically the longest possible whilst allowing the
maximum number of patients to be included. A negative outcome was defined as the pres-
ence of significant stenosis or occlusion in the AVF as indicated by vascular laboratory
notes i.e. inclusion in the dysfunction group.
Model fits were assessed by analyzing the residuals, R-squared values and variance
inflation factor values. Type-3 anova testing was performed to assess the effect of variable
order in the models. Variables were assessed for correlation to avoid multicollinearity.
Alpha values for statistical significance were taken to be 0.05.
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3.3 Results
Data was available for 47 patients who underwent a pre-operative assessment between
November 1, 2016 and December 31, 2017. All 47 patients underwent a pre-operative
SWE assessment and 32 patients underwent a pre-operative VVI assessment. 33 patients
ultimately had an AVF created in the study period, and all underwent one post-opearative
SWE assessment at 6 - 12 weeks. 40 healthy volunteers were recruited to act as a com-
parator group and all underwent SWE and VVI assessment. Patient and HV demographics
can be seen in table 3.1. Significant differences in pre-operative brachial artery diameter
(p < 0.05), age (p < 0.05) and body mass index (BMI) (p < 0.05) were observed between
the two groups. Pre-operative US measurements of SWE and VVI can be viewed in table
3.2.
Patient Group (n = 47) HV Group (n = 40) p-vale
Age (years) 66 ± 13 36 ± 15 < 0.05
Male (%) 55 45 0.34
BMI (kg/m2) 29 ± 6 23 ± 6 < 0.05
Diabetes (%) 38 0 -
Hypertension (%) 77 0 -
Pre-operative brachial artery diameter (mm) 5.0 ± 1.0 4.0 ± 0.6 0.002
SWE assessment (%) 100 100 -
VVI assessment (%) 100 68 -
Table 3.1: Patient and HV demographics
3.3.1 Pre-opearative US tests
Shear Wave Elastography
SWE maps were taken for all 47 patients, and all 40 volunteers. Significant differences
were seen for measurements of SWV between the patient and HV groups (patient SWV
3.2 ± 0.5 m/s, HV 3.4 ± 0.4 m / s, p = 0.03) (see figure 3.7). A statistically significant
negative association between age and shear wave velocity was observed (r = -0.2, p =
0.05), a scatter plot with a regression line fitted can be seen in figure 3.8. No significant
difference was observed between the left and right arm in 20 patients when assessed using
Wilcoxon ranked test (p = 0.70).
When considering the whole group (n = 87), no significant differences in SWV were
observed between subjects with diabetes and no diabetes (no diabetes 3.2 ± 0.5 m/s, dia-
betes 3.1± 0.6 m/s, p-value=0.1). A significant difference in SWV was observed between
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Measurement Patient Volunteer p-value
Shear Wave Velocity (m / s) 3.2 ± 0.5 3.4 ± 0.4 0.03
Radial Velocity (cm / s) 0.01 ± 0.01 0.01 ± 0.01 0.23
Radial Strain (%) 2.0 ± 1.5 1.6 ± 0.9 0.11
Radial Strain Rate (/s) 0.1 ± 0.1 0.1 ± 0.1 0.15
Radial Displacement (mm) 0.03 ± 0.02 0.02 ± 0.04 0.18
Longitudinal Velocity (cm / s) 0.03 ± 0.03 0.02 ± 0.02 0.02
Longitudinal Strain (%) 1.6 ± 1.7 0.9 ± 0.9 0.06
Longitudinal Strain Rate (/s) 0.1 ± 0.1 0.07 ± 0.06 0.03
Longitudinal Displacement (mm) 0.05 ± 0.06 0.03 ± 0.04 0.06
Table 3.2: Ultrasound Measurements
Figure 3.7: Boxplots of shear wave velocity values for patients and volunteers, horizontal lines inside the
coloured boxes indicate median values
subjects with hypertension and no hypertension (no hypertension 3.4 ± 0.4 m/s, hyper-
tension 3.1 ± 0.4 m/s, p-value=0.02) When only the patient group was considered, there
was no difference between those with hypertension and no hypertension (no hypertension
3.3 ± 0.7 m/s, hypertension 3.1 ± 0.3 m/s, p-value=0.4)
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Figure 3.8: Scatter plot of age and shear wave velocity measurements for both patients and volunteers,
with a regression line fitted. Vertical lines for each marker represent the standard deviation of a single
measurement. A significant negative association is observed, pearson’s r = -0.2, p = 0.05
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Velocity Vector Imaging
VVI post-processing was attempted on images from 32 patients, and all 40 volunteers.
VVI measurements were not possible, wholly or partially, in a number of patients (n = 6,
19 %). This was primarily due to problems associated with the patient’s ECG readings
(pacemaker n=1, 3 %, arrhythmia n=1, 3 %), and failure to obtain an ECG reading (n=1
3 %). The remaining patients (n=3, 10 %) produced vessel movement profiles that were
highly out of sync and could not be interpreted. This may have been due to imaging
technique, or highly dis-synchronous wall movement. Similarly, a number of HVs (n=6,
15 %) produced VVI measurements which were difficult to interpret. This was down
to a poor ECG trace (n=2, 5 %) and highly dis-synchronous wall movement (n=4, 10
%). Figure 3.9 shows the radial displacement pattern for one of the 3 patients with dis-
synchronous wall movement. VVI measurements were successful for the remaining cases.
Figure 3.9: VVI output for a patient showing a highly chaotic radial displacement pattern.
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Mean measurements from VVI can be viewed in table 3.2. The standard deviations
were large for all measurements, indicating a large amount of noise present in the data.
Significant differences were observed between the patient and HV group for measure-
ments of longitudinal velocity (patient 0.03 ± 0.03 cm / s, HV 0.02 ± 0.02 cm / s, p =
0.02), and longitudinal strain rate (patient 0.1 ± 0.1 /s, HV 0.07 pm 0.06 /s, p = 0.03),
with the HV group showing larger values for both measurements. Differences between
the patient group and HV group for measurements of longitudinal strain and displacement
were approaching significance (both p = 0.06).
No significant correlations with age were observed for any measurements from VVI.
There were no differences in subjects with diabetes or hypertension compared to those
without diabetes or hypertension for any of the VVI measurements assessed (all p > 0.05
when assessed with MannWhitney U-test). In 20 patients, no significant difference was
observed between the left and right arm using a Wilcoxon ranked test (p = 0.88).
3.3.2 Correlation between the measurements
The formula for the t-statistic for pearson’s r given N degrees of freedom is:
t =
r√
N−2
1−r2
(3.3)
For a t-statistic of approximately 1.671 and 71 degrees of freedom we can determine that
the cut-off value for a statistically significant r (p < 0.05) in this case is | 0.16 |.
A pair-plot demonstrating relationships between measurements can be seen in figure
3.10. From this plot it is evident that a number of correlations between the US measure-
ments are present. Pearson’s r statistic for these correlations can be seen in figure 3.11.
A weak negative correlation between SWV and radial velocity (r = 0.2) and longitudinal
velocity (r = 0.17) was observed. Significant positive correlations were observed between
all radial VVI measurements, and all longitudinal VVI measurements. The strongest cor-
relations were observed between longitudinal measurements.
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Figure 3.10: Pairwise scatterplots visualising relationships between ultrasound measurements from VVI
and SWE all US variables assessed. A number of linear correlations are clear in the data, such as between
radial strain, and radial strain rate. Other pairs such as shear wave velocity and radial strain rate show no
association
82
Figure 3.11: Pearson’s R statistic assessing correlation between pairs of ultrasound measurements from
VVI and SWE. This is essentially a statistical visualisation of the scatterplots visualised in figure 3.10
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3.3.3 Reproducibility and homogeneity of measurements
A random selection of 15 volunteers underwent US (SWE and VVI) scanning by an ad-
ditional operator, blinded to results of the first assessment. Strong agreement in measure-
ments of SWV was observed between the two operators when assessed using Pearson’s r
statistic (r = 0.92, p = 1×10−6, ICC = 0.88), a scatter plot with a regression line fitted can
be seen in figure 3.12. Acceptable agreement was observed for the VVI measurement of
radial displacement (r = 0.68, p = 0.005, ICC = 0.33), and can be seen in figure 3.13.
Figure 3.12: Scatter plot of shear wave velocity measurements from two operators, with a regression line
fitted. Vertical lines for each marker represent the standard deviation of a single measurement. Strong
significant correlation is observed, pearson’s r = 0.92, p = 1×10−6, ICC = 0.88, indicating good agreement.
3.3.4 Post-operative assessment and AVF outcomes
33 patients had an AVF created within the study period. Of the 15 patients with no AVF
created, 4 died before the AVF could be created, one refused the operation, and the cause
was unknown for the remainder.
The mean age of these patients was 65 ± 13 years, and mean BMI was 31 ± 8. 16
patients (48 %) had diabetes, and 27 (82 %) had hypertension. 7 patients had a lower
arm AVF (radio-cephalic), and 26 had an upper arm AVF (22 brachio-cephalic, 4 brachio-
basilic). Within the observation period, 9 AVFs were noted to have undergone some
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Figure 3.13: Scatter plot of VVI measurements from two operators, with a regression line fitted. Moderate
positive correlation is observed, pearson’s r = 0.68, p = 0.005, ICC = 0.33.
dysfunction. This was due to clinically significant stenosis (6 cases) and occlusion (3
cases).
After AVF creation the mean diameters of the arteries used increased from 3.8 ± 1.1
mm to 5.2 ± 0.7 mm (p = 2 × 10−6). The mean increase was 1.4 ± 1.1 mm. Similarly,
veins used in AVF creation increased in diameter from 4.0 ± 0.8 mm to 7.3 ± 1.6 mm
(p = 5 × 10−7). The mean increase was 3.2 ± 1.5 mm. These increases are visualised in
figure 3.14. When correlations between the variables were assessed, a significant but weak
positive correlation was observed between hypertension and pre-operative vein diameter
(r = 0.29, p < 0.05, see heatmap in figure 3.15).
In the same period, the mean shear wave velocity values of the brachial artery de-
creased. Shear wave velocity of the brachial artery decreased from 3.2 ± 0.5 m/s to 2.4
± 0.4 m/s after AVF creation (p = 8× 10−6). The mean decrease was 1.2 ± 1 m/s, and is
visualised in figure 3.14.
No statistical differences were observed between the group without dysfunction (steno-
sis which was noted to be affecting HD treatment and requiring intervention, or occlu-
sion), and the group with dysfunction. Pre-operative artery diameters were similar be-
tween the two groups (no dysfunction 3.7 ± 1.1 mm, dysfunction 4.0 ± 1.0 mm, p =
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0.5). Vein diameters were similar between the two groups (no dysfunction 4.1 ± 0.8 mm,
dysfunction 3.9 ± 0.6 mm, p = 0.4). Pre-operative shear wave velocity measurements
between the two groups were also similar (no dysfunction 3.2 ± 0.4 m/s, dysfunction 3.2
± 0.6 m/s, p = 0.8).
No difference was observed between the groups for measurements of radial velocity
(no dysfunction 0.01 ± 0.01 mm / s, dysfunction 0.01 ± 0.01 cm / s, p = 0.7), or radial
displacement (no dysfunction 0.01 ± 0.01 cm, dysfunction 0.02 ± 0.02 mm, p = 0.8).
Similarly, no difference was observed between the groups for measurements of longitudi-
nal velocity (no dysfunction 0.03 ± 0.03 cm / s, dysfunction 0.03 ± 0.04 cm / s, p = 0.7),
or longitudinal displacement (no dysfunction 0.03 ± 0.04 mm, dysfunction 0.05 ± 0.06
mm, p = 0.8).
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A
B
C
Figure 3.14: Changes in vessel morphology after AVF creation. A : arterial diameter, B : venous diameter,
C : shear wave velocity of the brachial artery
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Figure 3.15: Correlations between variables used in regression modeling
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OLS regression models were used to determine if pre-operative SWE measurements
were predictors of the final arterial or venous diameter post-AVF creation. Known risk
factors including pre-operative vessel diameter, hypertension, diabetes and gender were
included in both models. VVI measurements were not included in these models, due to
the lack of difference between patients and HVs, the lack of an age correlation, and the
large amount of noise present in the data.
Model 1 assessed the arterial diameter achieved, and can be seen in table 3.3. Pre-
operative artery diameter (p = 0.01) was the only independent determinant of arterial
dilation in linear regression modeling. Model 2 assessed the venous diameter achieved
and can be seen in table 3.3. No variables were significantly associated with venous
dilation. Variable inflation values were low for all variables, and significant variables
were found to be valid when assessed with type-3 anova. Residuals for both models can
be seen in figure 3.16.
Model 1 - artery diameter achieved B p-value Model 2 - vein diameter achieved B p-value
Hypertension 0 -0.57 0.07 Hypertension 0 -0.95 0.2
Diabetes -0.30 0.60 Diabetes 0.25 0.60
Gender male 0.21 0.70 Gender male -0.98 0.10
Pre artery diameter 0.26 0.01 Pre vein diameter 0.45 0.23
Brachial SWV -0.17 0.55 Brachial SWV 0.05 0.94
R-squared 0.29 R-squared 0.26
Table 3.3: OLS regressions modeling post-operative artery diameter (model 1) and post-operative vein
diameter (model 2)
Figure 3.16: Residuals for model 1 and 2, both showing a random distribution which indicates good fit.
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A logistic regression model was used to determine if any of the variables were asso-
ciated to the outcome of the AVF at three months. Model 3 assessed the outcome of AVF
creation at three months post-AVF creation. No markers were identified as associated to
the outcome of the AVF in this model, which can be seen in table 3.4.
Model 3 - AVF outcome B p-value
Hypertension 1.1 0.3
Diabetes 0.15 0.9
Vein diameter -0.32 0.6
Artery Diameter 0.20 0.6
Brachial SWV -0.5 0.6
Pseudo R-squared 0.07
Table 3.4: Logistic regression output modelling patient outcome as high or low-risk
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3.4 Discussion
This study aimed to determine if measurements of elasticity via SWE and strain via VVI
could act as risk-factors for AVF failure if used as part of the pre-operative workup for
AVF creation. Initially, the feasibility of the techniques needed to be assessed in the pe-
ripheral vasculature, by comparing reproducibility and homogeneity of the measurements
in the volunteer group and the patient group pre-surgery. Following this, US measure-
ments of SWV, and strain parameters from VVI were compared between a patient and
volunteer group.
Patients were then followed for up to 3-months post-AVF creation to determine if
any relationship to the 3-month outcome of the AVF existed. SWE identified increased
compliance in the brachial artery after AVF creation, and no post-operative relationship
was observed for VVI measurements. None of the variables assess pre-operatively were
statistically associated with the clinical outcome of the AVF in this small group of patients.
3.4.1 Pre-operative Assessments
Shear Wave Elastography
On initial assessment, the SWE method showed good reproducibility between operators,
a significant negative correlation with age was observed and no significant difference
was observed between the left and right arms of participants was seen, suggesting the
measurement is homogenous. These results demonstrated the feasibility of the technique
in vascular assessments. Pre-operatively, SWV of the brachial artery of the patient group
was lower than the HV group. As the velocity is related to the square root of Young’s
Modulus, these results indicate that the brachial artery of an elderly group of patients
with ESRD is more compliant than that of the healthy volunteers.
A negative correlation between SWV and age was observed, indicating that the brachial
artery becomes more compliant with age, and indicates possible assessment of AS via
SWE. Patients with ESRD have been shown to have increased AS, although previous
studies have found that the brachial artery compliance may not decrease with age [54,
179, 27, 191]. Different trends in carotid and aortic stiffness have been observed in pa-
tients with CKD [25], and it is possible that similar phenomena are being seen in the
brachial artery.
The SWE method is limited by a number of technical factors, mainly age and BMI.
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It was observed that some elderly participants showed arteries that were more tortuous
than younger participants. For some participants within this group, it was difficult to find
a suitable region of artery close to the cubital fossa that was parallel to the transducer
surface. High BMI resulted in shear wave velocity measurements taken at a greater depth
than in patients within the healthy BMI range. In younger participants with a healthy
BMI, a suitable patch of artery for shear wave velocity measurements was commonly
found just proximal to the cubital fossa.
On our machine (Siemens S2000), it was not possible to gate the SWV measurements
to the cardiac cycle. This is a limitation of the current technique, as one study in a single
volunteer has shown that shear wave velocity measurements in the carotid vary throughout
the cardiac cycle [41]. This limitation is noted in other vascular studies of shear wave
velocity [144, 94]. However, the strong inter-operator agreement, and lack of difference
between arms suggests that if there is some time dependent effect on these measurements,
the effect is too small to introduce a significant error in the results.
Velocity Vector Imaging
The VVI assessment demonstrated required only a 5 second cine-loop of the brachial
artery in a transverse and longitudinal view, which should present no problems for any
clinically qualified sonographer. VVI demonstrated acceptable reproducibility, and mea-
surements were homogenous between two arms. However, a large standard deviation in
the results suggests that the method could be further developed.
Differences in VVI measurements of longitudinal velocity and strain rate were ob-
served between the two groups, with higher values observed in the patient group. How-
ever, the large standard deviation in the measurement suggests that these results may be
affected by a large amount of noise, potentially due to the imaging technique, or limita-
tions in the speckle-tracking software.
No significant correlations with age were observed for any VVI measurements. Inter-
operator agreement for VVI measurements was acceptable, but lower than that observed
for SWE. This is potentially due to operator experience, and the requirement for high-
quality US images for VVI analysis.
In this study, VVI measurements were possible from each US cine-loop. However,
the VVI technique has a number of technical limitations. Some patients did not give re-
liable results due to underlying conditions interfering with the ECG trace. One patient
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had a pacemaker, with pacemaker spikes on the ECG masking some r-wave signals which
may have caused constructive or destructive interference due to pulse wave reflections.
Another patient with a cardiac arrhythmia had vessel movement profiles which were ex-
tremely irregular and difficult to interpret. This seems to be an unavoidable limitation with
VVI measurements, which rely on user interpretation to provide meaningful analysis of
the data.
Previous studies using VVI have been conducted primarily on the carotid artery in
healthy and patient groups. Ma et al [100] have shown that patients with pre-eclampsia
produce irregular velocity profiles and Cho et al [36] had similar findings in patients with
Takayasu’s arteritis. This suggests that in certain groups of patients, the vessel movement
is not synchronised. In this study, highly dis-synchronous wall movement was seen in a
small number of patients and volunteers, rendering interpretation of the results highly dif-
ficult. The observation in the healthy cohort suggests that this may be to probe movement
during video capture, as one would not be expect to observe these patterns in healthy in-
dividuals. The study of dis-synchronous wall movement requires more attention, in order
to rule out that this observation is simply a probe movement artifact.
For all assessments, participants were imaged seated, in a position which was com-
fortable and bearable. US measurements were simple, and no specialist equipment was
needed, as is the case for pulse wave velocity measurements, except the widely available
software packages on the US machine. A number of strong correlations between the mea-
surements themselves were observed. The heatmap in figure 3.11 demonstrates that all
VVI measurements correlated positively with each other. A weak correlation (r = 0.17)
between SWV and longitudinal velocity, and between hypertension and vein diameter (r
= 0.29) was observed. This information is required in order to avoid multicollinearity in
statistical modeling, which can cause errors in modeling coefficients.
The main limitation of the study is that the two groups were not age matched. Pa-
tients with ESRD are often aged, with other co-morbidities such as high BMI, diabetes
and hypertension, making it difficult to find a healthy comparator group. It is possible
that blood-pressure can affect the SWV and VVI measurements, and the effect of differ-
ent blood-pressure values warrants further study. However, it was nevertheless necessary
to perform the tests in a control group in order to pilot the technique in a non-clinical
(controlled) setting to develop the imaging protocols, and to determine if any age or dis-
ease related differences could be observed. Another limitation is the lack of comparison
with another AS marker such as PWV. This study was designed to develop and assess the
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technique of obtaining VVI and SWV measurements of the brachial artery - now that this
has been achieved, future work can compare this technique to PWV.
3.4.2 Post-Operative Followup
33 patients in this study progressed to AVF creation during the follow-up period. As
expected, arterial and venous diameters significantly increased after AVF creation. SWV
values in the brachial artery were observed to significantly decrease after AVF creation.
9 patients had some kind of AVF dysfunction within 3-months, as indicated from
vascular laboratory notes. US measurements were compared between the groups with
and without dysfunction, and zero statistical differences in any variables were observed
between the two groups. Variables were assessed using regression analysis to determine
if they affected the final venous and arterial diameter achieved, as-well as the clinical
failure of the AVF. Only pre-operative arterial diameter was significantly influential on the
arterial dilation achieved, which has previously been observed. Zero parameters studied
were found to be related to venous dilation, or to the clinical failure of AVFs.
Following AVF creation, a decrease in SWV of the brachial artery was observed. This
indicated that an increase in tissue compliance had occurred, assuming that the tissue
density had not dramatically changed. This effect could be due to structural remodeling in
the artery, the increased volume of blood in the artery, or both. Decreases in global arterial
stiffness have been reported previously, along with decreases in systolic and diastolic
blood pressure [15]. Further histological studies would be required to characterise the
observed changes in brachial artery elasticity.
The poor fitting model used to assess clinical outcome of the AVF indicates that these
measurements may be of limited use to predict AVF stenosis or occlusion. It is possible
that pre-morbidities such as diabetes and hypertension masked any effect from brachial
artery stiffness. Due to the small sample size, we did not control for AVF site. It is possi-
ble that brachial artery elasticity may have more impact on brachial AVFs, as opposed to
RC-AVFs.
The main limitation of this study is a small sample size, including only 33 patients
that progressed to AVF creation. To increase statistical power, we limited the variables
included in statistical modeling to those suspected to have the largest impact on AVF
outcomes. Whilst we controlled for the presence of hypertension, we did not assess blood
pressure. As noted, the effect of hypertension and blood pressure on SWV measurements
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warrants further study.
Venous measurements of SWV were not taken prior to AVF creation due to the thin,
and easily compressible nature of the venous wall. SWV measurements should be possi-
ble in the venous segment following AVF creation due to the increased volume of blood
which would reduce its compressibility, and the increased wall thickness. VVI measure-
ments were not taken after AVF creation, however this was due to purely logistical reasons
owing to the availability of the equipment (SWE was installed on 2 US machines avail-
able in the vascular lab, but VVI only on 1 US machine). VVI measurements would in
theory be possible in the venous segment of the AVF, and should be tracked easily due to
the thicker venous wall following AVF creation.
In conclusion both SWE and VVI showed good reproducibility and homogeneity.
SWE presents as the more feasible of the two due to a clear correlation with age, and an
observed reduction in SWV values following AVF creation. The VVI method is feasible,
but let down by a large standard deviation in the measurement and requires further de-
velopment. A decrease in SWV of the brachial artery was observed after AVF creation,
which indicates an increase in tissue elasticity. The only additional statistically signif-
icant result was that pre-operative artery diameter was associated with arterial diameter
increase post-AVF creation. No variables were associated with venous dilation or the clin-
ical failure of the AVF. Further research is required to determine if the increased elasticity
is due to structural remodeling of the artery. Larger cohort studies with longer follow-up
are required to determine if there is any relationship between SWE measurements and
AVF failure. 1
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Notes
1Work from this chapter is currently published as MacDonald, C., Ross, R., and Houston, J. (2018).
Shear wave velocity measurements of the brachial artery in a population with end-stage renal disease.
Biomedical Physics and Engineering Express, 4(5), 057002.
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Chapter 4
MRI and Ultrasound Comparison
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4.1 Introduction
MRI is an attractive diagnostic tool as it can provide excellent angiographic images, with
or without the use of contrast agent [47, 57]. Planken et al [136] established that contrast
enhanced (CE)-MRI was an accurate modality for providing pre-operative vessel diame-
ters in patients requiring AVF creation. Further work by the same group [137] reported
that CE-MRI was superior to US in detecting venous pathologies (most commonly upper
arm cephalic vein occlusions) in 73 patients prior to AVF creation.
However since 2006 there has been a marked decline in MRI based imaging involving
patients with end stage renal disease and AVFs. This is likely due to the association
between certain Gd-based contrast agents and nephrogenic systemic fibrosis, a fibrotic
disease of the major organs [88]. NCE-MRI methods are currently the safest option for
this cohort. The Gradient Echo ToF sequence is commonly used in MR angiography,
and relies on the inflow of blood to produce a hyper-intense signal. Various studies have
reported that this sequence can visualise, assess failure and locate stenosis in AVFs [57,
62, 86, 70].
Pre-operatively, very few studies have described the use of NCE-MRI to image the
vessels of patients indicated for AVF creation. Menegazzo et al (1998) [108] compared
ToF imaging with venography to assess the depiction of vein diameters prior to AVF
creation. ToF measurements were better correlated with subsequent surgical findings. In
2012, Bode et al [21] used CE-MRI and a NCE balanced turbo field echo sequence to
detect stenoses prior to AVF creation. The NCE-MRI detected 66 % of (non-significant)
stenosis found on CE-MRI, but importantly these were not seen on previous US imaging.
More recently a T2* Gradient Echo MEDIC sequence [78] has been used to highlight
lower limb vessels, indicating possible future uses for this in pre-surgical mapping or
surveillance of AVFs. The MEDIC sequence is a flow compensated 3D T2* weighted
gradient recall echo technique where multiple echoes are acquired during the TR period
via frequency encoding gradient reversals. The images acquired from each echo are then
combined to form a combination image benefitting from improved SNR. For non-contrast
measurement of blood flow velocity, the widely used technique of phase contrast MRA
(PC-MRA) is available [123] providing the opportunity for pre-operative MR assessment
of vessel structure and blood flow velocity to be used within a single modality.
A major strength of MRI compared to US is it’s ability to depict the central arterial
and venous vessels. Central vein pathology can be a cause for AVF failure, and cannot
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easily be detected by US imaging. In certain groups of patients, such as those with pre-
vious central line usage, screening for central vein stenosis could identify patients who
should not under go AV access creation, or identify patients who can. The use of MRI in
these patients would reduce the need for invasive DSA assessments, which are currently
considered the gold standard, but involve the injection of contrast agents, and radiation
dosing.
This chapter sought to answer the research question: is 3T MRI useful as part of the pre
and post-operative workup for a patients AVF?. Specifically, the objective was to examine
the performance of three (non contrast) MRI pulse sequences (namely MEDIC, ToF and
PC-MRI) for these purposes, in order to establish whether they may prove useful the pre
and post-surgical assessment of patients listed for AVF creation, before the possibility of
further studies assessing the central vessels in these patients. 3T NCE-MRI methods were
compared against the reference standard of US for the assessment of vessel geometry
and blood flow velocity in the arms of both patients and healthy volunteers at a single
time-point, and also in patient volunteers before and after AVF creation.
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4.2 Materials and Methods
4.2.1 Volunteer Recruitment
Ethical approval was obtained to recruit patients and healthy volunteers (HV) into this
study. Patients and volunteers were recruited to undergo at least one MRI and US scanning
session. For the patients, this was once before, and up to four times after AVF creation
over a period of 6 months, for HVs, this was a single scanning session.
Patient and volunteer recruitment was performed over the period covering Jan 2014 -
Dec 2016, and was managed by a member of the ReDVA project. Patients were recruited
from the vascular laboratory in Ninewells hospital and medical school if they were listed
for AVF creation within the study period. Healthy volunteers were recruited from staff
and students in Ninewells hospital and medical school, and NHS Tayside. Fully informed
consent was granted from each individual.
4.2.2 Ultrasound Examinations
For the US examinations all participants were seated with a pillow resting on their lap.
The arm under investigation was extended palm up on the pillow. A tourniquet was ap-
plied to the upper arm for venous measurements and released before arterial measure-
ments. Diameter measurements of the vessels were taken using electronic callipers. Peak
systolic velocity (PSV) values were measured as the highest single point on the Doppler
reading with an accuracy of 0.01 m/s. The velocity values obtained were subsequently
used as a guide to assist with identifying a suitable velocity encoding (VENC) value on
the subsequent phase contrast MRA sequences.
Pre-Operative Assessment
Lower Arm Evaluation
The cephalic vein was identified at its most distal segment, and diameter measure-
ments taken at this location. The diameter of the radial artery was measured at the wrist
position. An assessment was made of vessel uniformity and the presence of multiple
branches was noted, if present. The artery was then assessed in a longitudinal view using
Spectral Doppler to record the peak systolic velocity (PSV) and phasicity (presence of
reverse velocity component and a clear diastolic peak velocity component).
Upper Arm Evaluation
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The cephalic vein and brachial artery were identified at the cubital fossa and their
diameters were measured at this location. Vessel uniformity and branches were assessed
as before. As with the radial artery, the PSV was measured using a longitudinal view.
An oil capsule was then placed on the skin surface at the proposed location of the
surgical anastomosis in order to guide MRI imaging i.e. to ensure that the same anatomic
areas were observed using both imaging modalities (see figure 4.1).
Figure 4.1: Placement of oil capsule for a) upper arm imaging, b) lower arm imaging
Post-Operative Assessment
The vein was identified central to the anastomosis. Diameter and velocity measurements
were taken 6cm proximal to the anastomosis, and this process was also repeated for the
artery.
4.2.3 MR Imaging
All participants were placed head first and supine into the scanner bore with their arms
relaxed by their side. An 8-channel small flex RF coil was placed around the arm region
of interest. The participant was positioned slightly off-axis in relation to the scanner bore,
in order to ensure that the arm (anatomical area of interest) was as near as possible to the
isocentre of the magnetic field.
Morphology Assessment
A 2D gradient echo localiser sequence was used for initial visualisation of the proposed
anastomosis area. Following this, a 2D time-of-flight (TOF) MR sequence was applied in
an axial oblique orientation at either the upper or lower arm (see table 1) perpendicular to
the long bones, and region coverage was maintained at approximately 10-15 cm. Imaging
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parameters used were repetition time (TR) and echo time (TE) of 14 ms and 5.8 ms re-
spectively, flip angle (FA) of 18, and a 1.5 mm slice thickness (ST). Images were acquired
using a single average over a field of view (FOV) of 140 mm, with an imaging matrix of
512 x 512 pixels (no interpolation), and receiver bandwidth of 165 Hz/pixel. This was
followed by a 3D T2* Multi Echo Data Image Combination (MEDIC) sequence (TR/TE:
29/16 ms, FA: 30, slice thickness: 1.06 mm (176 slices in the imaging block), FoV: 136
mm, matrix: 512 x 512 pixels (no interpolation), and receiver bandwidth: 160 Hz/pixel)
over the same area.
Velocity Assessment
Through plane blood velocity measurements were obtained in the artery and vein of inter-
est at distal and proximal positions relative to the bifurcation or anastomosis site. A ret-
rospectively ECG gated 2D phase contrast MRA sequence (PC-MRA) was used to derive
velocity measurements (TR/TE: 99.7/7.62 ms, FA: 20, FOV 100 mm, matrix 192 x 115
pixels, receiver bandwidth: 440 Hz/pixel, VENC: 10-250 cm/s (depending on whether
artery or vein) and 16-64 temporal phases over the cardiac cycle).
4.2.4 Image analysis
The MEDIC, ToF and PC-MRI sequences were exported in DICOM format to an offline
computer. Osirix Lite (Pixemo, Switzerland) was used as a database, and for diameter and
area measurements. Transverse image slices from the MEDIC and ToF sequences were
used for ROI analysis of vessel diameter and area. Diameter measurements were made
of the vessel diameter in the major and minor axis for each image slice using electronic
calipers in Osirix, and vessel area was plotted as a function of distance from the anasto-
mosis or bifurcation (see figure 4.2). Anatomical landmarks (e.g. bifurcations of other
vessels) were used to register adjacent measurements between the two time-points. Trend
lines were plotted using a rolling 3-point average.
Semi-automatic segmentation and analysis of the PC-MRI images was undertaken us-
ing Segment (Medviso, Sweden). A ROI was drawn around the vessel of interest and
automatic propagation of the ROI was processed through all images in the series. Flow
and velocity information of blood in the vessel ROI was extracted (see figure 4.3). For
comparison with US, the diameters measured by MRI were averaged over a 1cm region
approximately 6cm from the anastomosis or oil capsule i.e. consistent with the US imag-
102
Figure 4.2: Osirix workstation showing 3 perpendicular slices of a patient’s AVF from MEDIC images
ing locations.
Figure 4.3: Segment workstation showing contour on a patients artery, and corresponding velocity wave-
form from PC-MRI images
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4.2.5 Statistical Analysis
All statistical analysis was conducted using RStudio (RStudio inc, US). All datasets were
assessed for normality using the Shapiro-Wilks Normality test. Statistical comparison
of means was subsequently performed using a students t-test for normally distributed
data, or the Mann-Whitney test for non-normal data. Paired equivalents were used when
appropriate. Bland-Altmann style plots were used to visualise agreement between the
modalities. Graphs were plotted using Python with the matplotlib and Seaborn packages.
An additional (junior) operator performed repeat measurements of the vessel diameter
from MEDIC MRI images. Agreement between two users was assessed using Bland-
Altmann plots.
4.2.6 Compliance with Ethical Standards
The study received ethical approval from the East of Scotland Research and Ethics Ser-
vice (EoSRES). Written informed consent was obtained from all individual participants
included in the study.
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4.3 Results
4.3.1 Imaging and Surgical Outcomes
Sixteen fully consented participants (table 4.1) were recruited into the study; 10 healthy
volunteers (HV1-10) and 6 patients with end-stage renal disease (PRF1-6) previously re-
ferred for AVF creation surgery. Three of the PRF participants were indicated for brachio-
cephalic AVF creation (PRF1, PRF3, PRF5) and three were indicated for radio-cephalic
AVF creation (PRF2, PRF4, PRF6). All participants underwent pre-operative vessel map-
ping using ultrasound (S200, Siemens, USA), performed by an experienced operator, and
magnetic resonance imaging (3T Siemens Magneton Trio-PrismaFIT, Erlagen, Germany)
performed by an experienced clinical research team. Pre-operative images from both
modalities were obtained on the same day. Post AVF surgery, all PRF participants under-
went ultrasound surveillance imaging at 6 weeks. Four of the PRF participants (PRF1,
PRF2, PRF3, PRF6) also underwent a single MRI surveillance session, 17 - 26 days after
surgery.
Patients (n = 16)
Age 44 ± 16
Male
Diabetes 4
Arterial fibrillation 2
Heart failure 1
Upper arm imaging 5
Lower arm imaging 11
Table 4.1: MRI study participants
All 16 participants were scanned successfully using both US and MRI, although initial
observation of the images revealed that the following exclusions were required: ToF: one
dataset (PRF5) - unreadable due to participant movement; MEDIC: one dataset (HV4) -
unreadable due to participant movement; PC-MRI: two datasets (PRF4, HV2) - arterial
VENC sub-optimal; US: one dataset (HV6) file data corrupted during storage. Figure 4.4
shows example axial image slices acquired at the radio-cephalic region of the upper arm
of a healthy volunteer using (i) T2* MEDIC and (ii) 2D ToF MRA.
Surgically, AVF creation was initially successful for all but one participant (PRF1). In
this unsuccessful case it was necessary to abandon the procedure due to calcification of
the vessels, although a second procedure was subsequently successful at a more proximal
site. Participant PRF6 developed a post-surgical infection at the anastomosis site, but with
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Figure 4.4: example axial image slices acquired at the radio-cephalic region of the upper arm of a healthy
volunteer using (i) T2* MEDIC and (ii) 2D ToF MRA.
no long-term complications.
4.3.2 Morphology results 2D TOF v MEDIC v US diameter compar-
isons
When data acquired using ToF, MEDIC and US were compared (figure 4.5), mean arte-
rial diameters were found to be consistent across all imaging modalities (3.2 ± 0.7 mm
for ToF; 3.4 ± 0.8 mm for MEDIC; 3.5 ± 0.7mm for US; p > 0.05 for all). However
statistical differences were noted when comparing the mean venous diameters measured
by ToF (3.5 ± 1.2 mm) to those measured by both MEDIC (4.4 ± 1.6 mm) and US (4.6
± 1.0mm); p < 0.05. Bland-Altman style plots (figure 4.6) demonstrate good agreement
between MRI (both MEDIC and ToF) and US for all artery diameters, with mean values
close to zero. However, a clear underestimation of venous diameters was observed for
data derived from the ToF sequence.
When participants were split into PRF (n=6) and HV groups (n=10), mean arterial
diameters were consistent when measured with US (3.5 ± 1.0 mm for PRF; 3.5 ± 0.5
mm for HV). However, mean arterial diameters were lower for the PRF cohort relative to
the HV cohort when derived from both NCE-MRA sequences (MEDIC: 3.0± 1.0 mm for
PRF, 3.8± 0.5mm for HV); (ToF: 2.7± 0.9mm for PRF, 3.5± 0.5mm for HV); p < 0.05
for each. For the veins, mean measured diameters were consistently smaller in the PRF
cohort relative to the HV cohort, irrespective of whether US or MRI was used (US: 3.9 ±
1.0 mm for PRF, 5.0 ± 0.8mm for HV; MEDIC: 3.0 ± 1.5mm for PRF, 5.3 ± 0.6mm for
HV; ToF 2.6 ± 0.8 mm for PRF, 4.0 ± 1.0mm for HV); p < 0.05 for all.
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Figure 4.5: Illustrations of arterial and venous diameter measurements - using ToF, MEDIC and US.
Figure 4.6: Bland-Altmann style plots depicting mean difference between: (a) artery diameter measure-
ments from MEDIC MRI and US; (b) vein diameter measurements on MEDIC MRI and US; (c) artery
diameter measurements on ToF MRI and US; (d) vein diameter measurements on ToF MRI and US.
4.3.3 Flow velocity results PC-MRA v US velocity comparisons
For arterial flow velocity measurements, the mean velocities measured by MRI (51.4±17.2
cm/sec) and US (53.2 ± 12.6 cm/sec) were similar (p > 0.05). When the data were con-
sidered on an individual basis, the bias between the MRI and US observations was 0.54
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and the MRI versus US root mean square (RMS) coefficient of variation (CoV) was 11.8
%.
Similarly, when the data were sub-divided into PRF and HV cohorts, the mean veloci-
ties measured by MRI and US were still consistent (PC-MRI: 49.8± 25.6 cm/sec for PRF,
52.2 ± 12/4 cm/sec for HV); and US: 55.0 ± 7.7 cm/sec for PRF, 52.0 ± 15/4 cm/sec for
HV); p > 0.05 for all. These values are displayed graphically in figure 4.7.
Figure 4.7: Boxplots showing mean blood flow velocity for PC-MRI and US
4.3.4 Pre and post-operative observations of vessel morphology and
flow
Pre-operative and post-operative arterial and venous diameter measurements were mea-
sured, but statistical testing of these measurements were not attempted since the number
of subjects involved was small (n=4). The RMS differences between the post-surgery
minus pre-surgery measured vein diameters were 3.2mm (ToF), 3.9mm (MEDIC) and
2.2mm (US), and for the arterial diameters the RMS differences were 1.7mm (ToF),
2.2mm (MEDIC) and 1.3mm (US). Looking in more detail at the vein morphology over
the full length of the MR imaging block, all veins studied developed larger cross-sectional
areas after surgery relative to their pre-surgical dimensions. However the cross-sectional
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area changes were not uniform across the full length of the vein area scanned (see figure
4.8).
Figure 4.8: Graphs depicting pre and post-operative venous area for participants (a) PRF1; (b) PRF2; (c)
PRF3; (d) PRF4. Areas of narrowing are visible in participants PRF3 and PRF4.
Arterial peak velocities were markedly increased after surgery. The RMS differ-
ences between the post-surgery minus pre-surgery measured arterial velocities were 164.3
cm/sec (PC-MR) and 183.6 cm/sec (US). Post-operatively the arterial waveforms were
altered, with loss of their characteristic tri-phasic pattern (a lack of reverse velocity com-
ponent and a loss of a clear diastolic peak velocity component).
4.3.5 Repeatability of MRI diameter measurements
Measurements from the MEDIC MRI images were found to be reproducible when as-
sessed by a junior researcher (see figure 4.9). Mean difference for all cases were around
zero, with around 10 % standard deviation.
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Figure 4.9: Bland-Altmann style plots depicting mean difference between two operators measuring arterial
and venous diameter throughout the length of the AVF for two study volunteers.
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4.3.6 Imaging features of the TOF and MEDIC MR Sequences for
AVF Visualisation
On all pre-surgical images (ToF and MEDIC) the vessel lumen flow signal intensity was
hyper-intense, as expected. However on the post-surgical images the vessel lumen was
hyper-intense at locations proximal to the anastomosis but the signal was lost within the
anastomosis itself. On the ToF images it was not possible to discern the vessel pathway
of the anastomosis since the vessel edges were unclear, but on the MEDIC images the
vessel edges remained consistently and clearly visible - thus enabling a better view of
the stationary structures associated with the anastomosis. Example post-surgical MEDIC
images are shown in figure 4.10.
Figure 4.10: Example 3T Gradient-Echo MEDIC MR images of the elbow region of two different par-
ticipants, (i) and (ii), who each underwent AVF placement. (A) and (E) show examples of high luminal
signal intensity in the cephalic veins at a location a few cm proximal to the anastomosis site. The luminal
diameter is slightly enlarged in participant (i) and grossly enlarged in participant (ii); (B) and (F) show
examples of hypo-intense luminal signal intensity together with hyper-intense vessel edge signal intensity
at the approach to the anastomosis site; (C) and (G) each illustrate the flat swing site location of the anasto-
mosis; and (D) and (H) each illustrate the hyper-intense luminal signal intensity in the brachial artery distal
to the anastomosis site. The images were obtained 24 days post-surgery for participant (i) and 26 days
post-surgery for participant (ii).
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4.4 Discussion
In this pilot study, the feasibility of using 3T MRI techniques for the assessment of up-
per and lower arm blood flow geometries and velocities at potential AVF sites is de-
scribed. For morphological assessments, the MRI T2* MEDIC technique used compared
favourably against the current reference standard of US, with very similar diameters ob-
tained in patients and healthy volunteers. Further, the combined observation of hypo-
intense vessel lumen with hyper-intense vessel edges in the vicinity of the anastomosis
using MEDIC was a consistent finding in the four examples studied. Further studies
are warranted to explore this pattern of contrast behaviour, but initial evidence suggests
that it may have the potential to assist with the visualisation of AVF remodelling events.
Increased knowledge of the remodelling process of arteriovenous fistulae is required to
help improve scientific understanding of AVF failure, and ultimately to facilitate the pre-
operative identification of patients whose fistulae may fail to reach maturation. Current
guidelines recommend physical examination or US, but these cannot provide the anatom-
ical detail required to increase the knowledge of the remodelling process. The purpose
of this work was to explore wider imaging opportunities as an alternative pre-operative
assessment to gain extra anatomical information. We utilised two MRI sequences (ToF
and MEDIC), alongside US to compare the geometries of arteries and veins in patients
with renal failure (n=6) and healthy volunteers (n=10). In a subset of the patients, AVF
remodelling was also monitored post-surgery. A comparison was made with US, rather
than patient outcome due to the small number of patients recruited into the study, and it
was deemed necessary to determine that the modalities were in agreement for vessel di-
ameter measurements before MRI could be considered as a useful tool to measurem these
diameters in these patients.
The MEDIC sequence was in agreement with US for all morphological measurements
made across the whole group (n=16). However, the ToF sequence underestimated the di-
ameter of the cephalic vein relative to both MEDIC and US. Although the ToF sequence
can be useful in detection of stenosis, these results suggest that if the depiction of accu-
rate vessel diameter information is important, then MEDIC would be a better choice. The
strong agreement seen between the MEDIC sequence and US confirms that this may be
a viable modality for mapping patient vasculature prior to AVF surgery. An additional
advantage is that MEDIC was able to depict both the arterial and venous system in the
arm in a single session, whereas ToF was unable to depict adequately the venous vessels
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in some cases. Importantly, US is recognised by current Kidney Disease Outcomes Qual-
ity Initiative (KDOQI) guidelines - thus the agreement between the two modalities also
helps to provide an indirect validation of the MEDIC sequence for assessment of vessel
morphology. However, it is important to state that the MEDIC sequence is unproven for
conventional clinical MR angiography and we would not recommend it for radiologi-
cal stenosis assessment since formal performance studies (e.g. comparisons with DSA)
have not been done. In this research study we have used MEDIC specifically for vessel
diameter tracking.
The MEDIC and US morphology measures were generally in good agreement with
each other. It is possible that the higher SNR of the 3D MEDIC sequence enabled clearer
visualisation of the vessel diameters relative to those of the ToF images. Further, the
presence of the higher signal vessel edge detail on MEDIC (clearly seen in the anastamo-
sis regions on the patients) may additionally contribute to the true vessel width not seen
on 2D-TOF. From the perspective of US, a possible concern is the fact that tourniquets
are routinely used to instigate a level of venous congestion potentially affecting the vein
diameters. However, work presented by van Bemmelen et al [178] determined that differ-
ences between US diameter measurement values obtained with and without a tourniquet
were not significant for either the cephalic or the basilic vein. They concluded that vein
diameters are affected by warm water immersion, but not the use of a tourniquet.
The lack of MRI contrast media used in this study completely removes any possibility
of nephrogenic systemic fibrosis or contrast induced nephropathy. The MEDIC sequence
has the advantage of acquiring the imaging in 3D - thus allowing measurements to be
made throughout the length of the vessel, unlike selective measurements from US. Fur-
ther, the MEDIC does not appear to suffer from through-plane signal losses in quite the
same way as ToF. An extension to consider the central vessels would also be feasible as
part of a future study. Previous research by Planken et al [136] has reported that contrast
enhanced CE-MRI is more accurate than US when comparing diameter measurements
made during AVF surgery, but no other similar study has been performed using a NCE-
sequence. In our study, the radial artery diameter in the PRF participants as measured
by MEDIC was in agreement with literature values measured by US [81]. Vessels used
for AVF creation were above the recommended minimum vessel diameters stated in the
literature [107, 163, 183].
Our results show that, pre-operatively, the vessels can have a heterogeneous cross-
sectional area. The implications of this for AVF maturation requires further study. It is
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possible that narrower (but non-stenotic) regions which exist pre-operatively, may be more
prone to stenosis development post-AVF creation. Post-operatively, vessels had achieved
or were approaching the recommended diameter of 6mm for cannulation. This adds to
the sentiment that pre-operative vessel diameters are not the major predictor of matura-
tion that some studies would suggest. Heterogeneous changes in the venous segment of
an AVF have been observed before [161, 63]. In this study, we included a pre-operative
analysis, enabling us to determine if any areas had undergone a decrease in area. It is pos-
sible that the areas of post-operative narrowing observed could be the result of neo-intimal
hyperplasia, and that the areas of lower dilation are related to local endothelial dysfunc-
tion or abnormal flow patterns. However, this would need to be determined by further
studies involving larger cohorts, multiple post-surgical analyses and/or haemodynamic
simulations.
Few studies have focussed on the changes that occur in the arterial segment, post AVF
creation. Corpataux et al [39] found that the radial artery did not significantly change over
a 3-month period. However, we noted large increases in the CSA of the radial arteries
studied. The observations noted by us may corroborate the use of MRI for providing
additional anatomical data which may form part of the larger picture of AVF-remodelling.
The purpose of this study was not to demonstrate the diagnostic ability of the MRI
sequences for AVF stenosis detection, although regions of narrowing were identified in
the venous segment of 2 AVFs. One of these participants (PRF3) did develop a stenosis
at a later date which was detected by routine US imaging. Further work is needed to
determine the pattern of stenosis formation post AVF, and whether MRI may have a role
in targeted post-operative stenosis screening.
MRI is rarely used in a clinical setting with ESRD patients due to financial constraints,
patient contraindications and concerns over the use of MRI contrast agents. Contraindi-
cation rates to MRI imaging of around 10 % in patients with ESRD have been reported
previously [47, 134]. Research involving MRI in patients on, or awaiting haemodialysis
has also slowed considerably since the occurrence of NSF. Non-contrast enhanced se-
quences such as black-blood or ToF MRI have been studied previously [161, 63], and the
relative limitations of each technique are reported. The MEDIC sequence used in this
study (a gradient echo technique with T2* weighting) provides good agreement with US
measures, but in common with ToF techniques it also suffers from inflow-related signal
losses at the anastomosis. However, the MEDIC sequence does provide good vessel edge
detail at the locations in and around the anastomosis, and it is possible that this may prove
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to be useful as a surveillance tool to characterise the development of stationary structures
such as possible stenosis sites.
This study has several limitations. Firstly, detailed optimisation work was not per-
formed on the ToF sequence to maximise the vessel/background contrast for use at the
chosen anatomical location - the vendor default parameters were utilised. The flip angle
was slightly lower than one might normally expect, although since we were observing
relatively slow flow within the veins the use of a larger flip angle may have resulted in
partial saturation of the venous signal. It is difficult to optimise the sequence when both
arteries and veins are being observed, although we accept that the negative effect of using
a smaller flip angle will be an elevated signal from stationary tissue. Lower flip angles
were also necessary in order for the acquisition to stay within acceptable SAR limits on
our 3T scanner for the chosen TR. Other experimental complexities included the fact that
the anatomy was, by definition, positioned at the periphery of the scanner bore in an area
of relatively heterogeneous magnetic field leading to unavoidable regions of inhomoge-
neous signal intensity. Finally, we were not able to apply fat suppression because doing
this would have resulted in a longer sequence TR leading to unacceptably long scan
times. The TR was also implemented with consideration of the expected venous flow
velocities likely to be present in the healthy volunteers. We estimated that the slowest
diastolic blood flow velocities present would be about 10 cm/sec, and using an estimate
that the TR would need to be equal or greater than the slice thickness (1.5 mm) divided
by the minimum flow velocity (10 cm/sec) to allow full in-flow of unsaturated blood i.e.
the TR would need to be a minimum of approximately 15 ms. Our choice of TR 14.5
ms was therefore at the limit in terms of the slowest blood flow velocities likely to be
encountered. However since the cardiac cycle was postulated to involve velocities mostly
above 10cm/sec, we felt that using this short TR would be the best solution to ensure the
shortest scan time - and lower chances of subject motion artefacts. We also used a TE
of 5.8ms (the shortest TE to acquire fat/water out of phase images at 3.0T), which was
implemented to ensure that the signal from water and fat were out of phase thus helping
to minimise stationary background tissue signals a little further.
Other modern MRI pulse sequences are potentially available for non-contrast en-
hanced visualisation of the vascular system. These include, for example, black blood
spin echo sequences (utilising double or triple inversion pulses to null the signal from
the vessels), and cardiac gated gradient-echo based sequences that typically use inversion
recovery along with a steady state free precession read-out after a systolic inflow period
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to allow movement of hyper-intense blood into the imaging plane. Common examples
of these are Non Contrast MRA of Arteries and Veins (NATIVE, Siemens), Quiescent
Interval Steady State (QISS, Siemens); Balanced Triggered Angiography Non Contrast
Enhanced (B-TRANCE, Philips); Inhance Inflow IR (IFIR, GE) and Time Spatial Label-
ing Inversion Pulse (TimeSLIP, Cannon). These sequences may be useful in the future
when it becomes possible to optimise them easily for arteries and veins interchangeably.
In summary, our study has demonstrated that the MEDIC sequence can offer accurate
depiction of both the arterial and venous dimensions in healthy volunteers and for pa-
tients requiring detailed vessel mapping of AVF sites. This information can be acquired
in a single imaging session and does not rely on contrast agent injections, which makes
it suitable for imaging wider patient groups with ESRD. This pilot study has demon-
strated that non-contrast enhanced MRI can be used to describe vessel morphology and
blood flow at anatomical sites associated with AVF surgery - with results comparable to
the reference standard of US. Additionally, the pattern of image contrast associated with
the MEDIC sequence at the anastomosis site may assist with future studies designed to
examine the AVF maturation process without the need for contrast agents. 2
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Notes
2This work is currently publish MacDonald, C. J., Gandy, S., Avison, E. C. M., Matthew, S., Ross,
R., and Houston, J. G. (2018). Non-contrast MRI methods as a tool for the pre-operative assessment and
surveillance of the arterio-venous fistula for haemodialysis. Magnetic Resonance Materials in Physics,
Biology and Medicine, 31(6), 735745.
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Chapter 5
MRI and CFD Variation
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5.1 Introduction
CFD is a well-known tool in engineering, used to assess the flow of fluids in silico. This
computational method is applied in cardiovascular engineering to predict and analyze
blood flow patterns in complex situations, such as cerebral aneurysms, valve prosthesis,
stented vessels, and AVFs [117]. Commonly, these studies are performed using 3D ge-
ometries segmented from medical images, such as CT and MRI, with or without contrast
agent. Patients with renal failure cannot receive Gd-based contrast agents commonly used
for MRI [71], so NCE-MRI sequences are used to image blood vessels in these cases.
Multiple NCE sequences exist, including the well-known ToF, and newer sequences such
as the MEDIC sequence.
The accuracy of CFD in predicting flow dynamics depends on a series of factors in-
cluding the boundary conditions, turbulence modeling, meshing techniques, researcher
experience, and geometrical accuracy. With the increased use of CFD in the assessment
and planning of medical devices, the accuracy of the geometries used in simulations is
critical to informing design decisions, and assessing disease pathology. Recently, the
American Food and Drug Administration (FDA) has begun to consider a good practice to
use computational models in the design process of medical devices. The FDA conducted
a multi-center study to compare CFD results to an experimental model, and observed a
large degree of variability between research groups [167]. Another large study conducted
by The International Aneurysm Challenged observed wide variability in CFD results be-
tween researchers [177]. Similarly, variations in results have been observed when seg-
mentations from MRI images and CT images are compared, and when imaging of the
same participant is undertaken at different time points [172], suggesting that deviations in
geometry are an important factor in WSS variation. It is possible different MRI sequences
can introduce similar variability into blood vessel segmentation, and, consequently, the
CFD analysis.
WSS has been identified as having a significant effect on the development of stenoses
in AVFs, and has been studied extensively using CFD. In these studies a number of dif-
ferent MRI sequences have been used in geometry acquisition [29, 63, 50, 161]. Using
the AVF as a model for segmentation and CFD, the aim of this study was to examine
the differences in geometric and CFD-derived parameters occurring when different MRI
sequences (namely MEDIC and ToF) are used for initial imaging.
In order to assess the error introduced by changing MRI sequence, a series of phan-
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toms simulating morphological features of the AVF were scanned using both ToF and
MEDIC. Geometrical features were quantified along many points to compare MEDIC
and ToF, and to profile differences under controlled circumstances. WSS quantities were
obtained from patient-specific CFD simulations using geometries from the two MRI se-
quences. The results from these simulations were compared to demonstrate the differ-
ences resulting from a changing in MRI sequence.
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5.2 Methods
Section 5.2.1 of the methods section describes those methods which were common for
the phantom and the patients. First, the imaging protocol is described, namely the MRI
parameters used, and the order of imaging sequences. Second, the segmentation of the
vessels, and the process of generating geometrical data is described. Finally, analysis
of this geometric data is then described in the context of assessing differences between
the two MRI-sequences. Section 5.2.2 describes methods which were unique for the
phantom. The phantom manufacture is described, along with the process of analyzing the
signal distributions and the effect of the phantom geometry on the signal. Section 5.2.3
describes methods which were unique for the patients . The imaging of the patients is
described, followed by the CFD protocol, and the generation/processing of the WSS data.
The patient cohort, and scanning procedure are identical to that of the previous chap-
ter, however to allow the chapter to stand-alone, the procedures are reproduced here.
5.2.1 Common methodology
MRI Imaging
All images were acquired on a 3.0 T PrismaFIT scanner (SIEMENS, Erlangen, Germany)
with an 8-channel small flexible array coil. A 2D gradient echo localizer sequence was
used for initial visualization of the area of interest. Following this, a 2D ToF MR se-
quence was applied in an axial oblique orientation and region coverage was maintained
at approximately 10 - 15 cm. Imaging parameters used were TR and TE of 14; 5.8 ms re-
spectively, FA of 18◦, and a 1.5 mm ST), FOV of 140 mm, with an imaging matrix of 512
x 512 px (no interpolation), and receiver bandwidth of 165 Hz / px. This was followed
by a 3D T2* MEDIC sequence (TR/TE: 29 / 16 ms, FA: 30, ST: 1.06 mm (176 slices in
the imaging block), FoV: 136 mm, matrix: 512 x 512 px (no interpolation), and receiver
bandwidth: 160 Hz / px) over the same area. The MRI sequences had similar voxel sizes,
with voxToF = 0.273 mm and voxMEDIC = 0.266 mm.
Vessel Segmentation
All images were segmented using the sweeping method available on SimVascular (Stan-
ford University, CA, USA), by an experienced cardiovascular engineer with 5+ years ex-
perience. Nodes of 3D splines were manually positioned near the center of the vessel for
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working as sweeping pathlines. Next, the 3D scans were interpolated onto a sequence of
planes perpendicular to the pathlines, where 2D closed-loop splines segmenting the vessel
lumen are obtained. Finally, the closed-loop spline segmentations were lofted together to
form the 3D tubular models with smooth transition between the segmented planes. These
models were exported as finely-spaced stereolithography files for geometry analysis and
CFD meshing.
This method has many advantages in contrast to selecting individual voxels, and ap-
plying the marching cubes algorithm for obtaining the vessel wall. Voxel segmentation
normally require some sort of thresholding, whose accuracy is very sensitive to pixel
contrast and noise. In contrast, the 2D closed-loop spline are inherently smooth, the seg-
mentation is not bound to voxel size, and are less sensitive to random noise.
Geometry Analysis
To compare geometric features (primarily model area and spatial projection) between the
MRI sequences it was necessary to define an origin point shared between the images. For
the phantom models the origin point was defined as the first segment of vessel to enter the
phantom box area. For the patient models the origin point was defined as the point at the
anastomosis where the vein centerline intersects with the artery centerline for the patient
models.
Geometrical features from the segmented models were measured as per published
methods [37]. Vessel centrelines in the form of splines were extracted using the maximum
inscribed sphere radius method [9]. The distance along the centerlines to the defined ori-
gin point s was defined as a topological 1D coordinate system to locate and compare the
geometrical features of the vessel. Thus the Cartesian position of any point of the center-
line splines was found from the distance along the centerline as γ(s) = (x(s), y(s), z(s)),
where the distance coordinate s was obtained from a line integral of γ using any arbi-
trary parametric coordinate. The vessel cross-sectional area A = A(s) was obtained by
integrating slices of the geometrical models perpendicular to the centerline.
Agreement between MEDIC and ToF phantom images was assessed using Bland-
Altmann methodology [19]. For each area measurement, the mean and difference be-
tween the model areas were calculated. This was done for the full length of the straight
phantoms, and for a length of 5 cm centered on the curve center for the curved phantoms.
Measured parameters such as area were also interpreted numerically through the use
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of an error metric which was essentially defined as the summed difference of the param-
eter, divided by its average
Ef =
2
n
n∑
i=1
∣∣∣∣fT,i − fM,ifT,i + fM,i
∣∣∣∣ , (5.1)
where n is the number of sampled data, and fT and fM are any quantity f obtained from
the ToF and MEDIC images, respectively. Ef takes a value of zero for identical measure-
ments, and increases as the error between the measurements increases.
5.2.2 Phantom Methods
Phantom Preparation
Two phantom setups were manufactured, a straight tube aligned with the MRI scanner
z-axis, and a loop swing. The first setup consisted of an open acrylic box, with a couple
of supporting structures to a plastic tube with its inlet and outlet points on the opposite
walls of the box. Three phantoms of this type were manufactured, with tube diameters
(D) 2; 3; 5 mm. The inlet of the tubing on one side wall of the box was connected to a
water source and a pulsatile flow pump (Cole Parmer, Masterflex Digital Pump System,
Germany). Each phantom was imaged with water flowing at flow rates (Q) of both 0.5;
1.0 L / min. With water density ρ = 1e3kg/m3 and dynamic viscosity µ = 1e−3Pa/s,
the Reynolds number
Re =
4
π
ρQ
µD
(5.2)
of the phantoms range in 2,100–10,600, indicating that the flow conditions are either
transitional or turbulent.
The second phantom setup consisted of an open acrylic box with both inlet and outlet
points of a tube of 5 mm in diameter positioned on the same wall. In this case, three
plastic cylinders were glued into the phantom body, two of which acted as supporting
structures, and the most distal one as a wrapping post (curve-H), as in figure 5.1. This
setup was then repeated with the tubing wrapped around the center cylinders (curve-L),
with the effect of reducing the curvature. The effect of this was to change the ‘sharpness’
of the curve. All phantoms were filled with a small amount of water in order to prime the
scanner.
All phantoms were placed into the scanner bore with the center of the phantom aligned
with the scanner isocenter.
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Figure 5.1: Schematic of the straight (left) and curved (right) phantom setups.
Phantom Signal Analysis
In order to profile each imaging sequence, signal intensity measurements were taken using
FIJI (figi.sc) [157]. Circular RoIs were used to measure signal from the flowing water,
background and stationary water sources in the image. This was done manually for each
slice in the series. Signal intensity values were normalized using a min-max normalization
algorithm available in scikit-learn [132]. Signal distributions were visualized graphically
using the “Seaborn” and “matplotlib” libraries in Python 2.7.
The STL model for the curved phantom was used to assess correlations between the
signal intensity to the flow angle relative to the magnetic field direction in the curved
phantom. Tangent unit vectors t̂ = dγ/ds were sampled at intervals ∆s = 1mm along
the centerline. The metric
Γ = t̂ · B̂0 (5.3)
defined by the dot product between Γ and the B0 (z-axis) unit vector was calculated for
each instance in order to assess the effect of flow-direction. Γ takes values of 0 for flow
parallel to B0, and values of 1 for flow perpendicular to B0. Correlations between Γ and
the signal intensity were assessed graphically, and with Spearman’s correlation statistic.
Similarly, correlations between signal intensity and the first spatial derivative of Γ were
assessed:
Γ′ =
dt̂
ds
· B̂0 (5.4)
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5.2.3 Patient Methods
Patient Preparation and Imaging
Four patient volunteers with end-stage renal failure who had been referred for AVF cre-
ation surgery were recruited into this study from our institution. All volunteers provided
informed written consent, and ethical approval was obtained. Two of the patients were
indicated for brachio-cephalic AVF creation (PRF1, PRF3) and two were indicated for
radio-cephalic AVF creation (PRF2, PRF4). Post AVF surgery, all patients underwent an
MRI surveillance session, 17–26 days after surgery.
All volunteers were placed head first and supine into the bore with their arms relaxed
by their side. An 8-channel phased array RF coil was placed around the arm of interest.
The patient was positioned slightly off-axis in relation to the scanner bore, in order to
ensure that the arm (anatomical area of interest) was as near as possible to the innocenter
of the magnet. The site of the anastomosis was identified by palpable thrill and was
marked by positioning an cod liver oil capsule on the skin adjacent to the site.
Volunteers had one additional sequence added to their protocol. A phase-contrast (PC)
MRI was performed, both proximally and distally to the anastomosis, in order to measure
the patient-specific flow rates at each branch of the AVF. Imaging parameters used were
TR/TE: 99.7 / 7.62 ms, FA: 20◦, FOV 100 mm, matrix 192×115, receiver bandwidth: 440
Hz/pixel, VENC: 10 -250 cm s (depending on whether artery or vein) and 16–64 temporal
phases over the cardiac cycle. Velocity wave-forms for the blood flow were produced by
semi-automated segmentation on Segment (Medviso, Switzerland). The principle of mass
conservation is not precisely obeyed throughout the entire pulse time, when the flow rates
through all exits of the AVF are summed. This happens for apparently three reasons:
instrument error, pulse variability from the times when the proximal and distal scans were
made, and blood vessel compliance.
CFD
The CFD meshing and processing were both performed with HELYX v.2.5 (Engys, UK)
by an experienced cardiovascular engineer with 5+ years experience. A hexahedra-dominant
octree algorithm was used for meshing, where the STL files from the image segmentation
were used to define the mesh geometry. The mesh surface was divided by four patches:
wall, proximal artery, distal artery, and proximal vein; at which the boundary conditions
were applied. Most cells had sides of 250 um, and a inflation prism layer of five cells from
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50 - 125 um covered the wall patch. The walls were considered rigid, and the boundary
conditions of all exits of the fistula were specified according to the patient-specific flow
rate pulses obtained from the PC-MRI scans. In order to avoid the error introduced by the
difference between scanning the pulse at the proximal and distal sections, only the flow
rates of the proximal section were used, and the distal flow rate was obtained from the
the principle of mass conservation. In the case where a distal vein was present, the distal
arterial pulse was also used, and the distal vein flow rate was estimated by the principle of
mass conservation. The pulses were applied with parabolic velocity profile onto circular
patches. Blood was considered a Newtonian fluid with dynamic viscosity µ = 3.5e−3Pa s
and density ρ = 1.06e3kg/m3, and flow condition was laminar. A large eddy simulation
was run to validate the laminar flow hypothesis.
Since it is believed that WSS has significant influence in the patency of AVF by its
role in the genesis of intimal hyperplasia [145], both time-averaged WSS
TAWSS :=
1
T
∫ t0+T
t0
τw dt , (5.5)
and oscillatory shear index (OSI)
OSI :=
1
2
1−
∥∥∥∫ t0+Tt0 τw dt∥∥∥∫ t0+T
t0
‖τw‖ dt
 (5.6)
were used in the analysis. In Eqs. 5.5 and 5.6, τw is the WSS tensor, T is the pulse period,
and t0 is a point in time. The OSI shows whether the τwn̂ vector oscillates on a single
pulse orientation (OSI = 0.0) or oscillating between positive and negative orientations
(OSI = 0.5) during the pulse period, where n̂ is the surface normal vector. Time averaged
quantities were measured in the third pulse (i.e., t0 ≡ 2T ) of the simulation in order to
remove flow-dependent effects.
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5.3 Results
5.3.1 Phantom Signal Analysis
The curved phantoms suffered from a signal loss artefact near the curve centre on MEDIC.
A number of features of the signal distribution were common to all phantom cases (see
figure 5.2):
• The signal from flowing water was similar for both sequences.
• Signal from the water used to prime the scanner was higher on the MEDIC than the
ToF.
• Background noise was higher for the ToF image series.
Figure 5.2: Histograms for MEDIC and ToF signal distributions. Noise is lower on MEDIC, and stationary
water signal lower on ToF. Flowing water signal is similar for both sequences.
Flow direction data was generated from the 2 curved phantoms as described, and is
visualized in figure 5.3. Signal intensity was plotted alongside Γ, and no clear trend
was observed. When the signal intensity was plotted alongside the first derivative, Γ′, a
consistent negative correlation was observed for the MEDIC sequence, but not the ToF.
The signal intensity of the MEDIC exhibited a strong negative correlation with Γ′, for
both phantom geometries, as assessed with Spearman’s correlation coefficient (curve-L,
r = −0.89, p < 0.05; curve-H, r = −0.85, p < 0.05). No such observation was observed
consistently on the ToF images. This is visualised in figure 5.4. The cross-sectional area
error metric EA for the phantom can be seen in table 5.1.
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Γ
Figure 5.3: 3D visualization of curve-H phantom, showing the sampled points along the vessel colour-
coded to the values of Γ. As expected, Γ takes a value of zero when flow is at a right angle to B0 (blue
arrow).
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Figure 5.4: Signal dependency on rate of change of flow direction for: (a) curve-H MEDIC, r = −0.85,
p < 0.05; (b) curve-H ToF, r = −0.85, p < 0.05; (c) curve-L MEDIC, r = −0.89, p < 0.05; (d) curve-L
ToF, r = 0.47, p < 0.05;
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Phantom EA (-) Mean Difference in Diameter (mm)
Straight, 5 mm 0.04 -0.02 ± 0.12
Straight, 3 mm 0.20 -0.3 ± 0.14
Straight, 2 mm 0.22 -0.26 ± 0.16
Curved-H, 5 mm 0.03 0.00 ± 0.20
Curved-L, 5 mm 0.10 0.20 ± 0.60
Table 5.1: Error analysis between MEDIC and ToF sequences for phantom STL measurements at a flow
rate of 1L / min
Bland-altmann analysis revealed that for the straight phantoms, mean differences were
between 0 – 13 % for all cases. Differences between the imaging sequences increased as
the vessel radius decreased, but no other clear trend was obvious. Bland-altmann plots for
these phantom geometries can be seen in figure 5.5 a. A larger degree of variability was
observed when the flow rate was changed as can be visualised in figure 5.5 b.
For the curved phantoms, the largest deviation was seen at the centre of the curve.
Bland-altmann plots for these phantom geometries can be seen in figure 5.5 c. Values for
EA, along with mean differences in radii for the phantom cases are reported in Table 5.1.
5.3.2 Patient Analysis
Segmentation using both MEDIC and ToF sequences was possible for all MRI series.
Nevertheless, the 3D segmentations of the same patients were not completely identical
when comparing the MEDIC and ToF sequences. For example, and in agreement with
the previous chapter, the depiction of arterial area was generally larger for the MEDIC,
although the lumen area, shape and curvature were variable throughout the length of all
vessels studied. The segmentation end points were at different positions, because the
FoV of the two sequences were not over a precisely shared volume. Signal drop-out
was observed in the area near the anastomosis for both ToF and MEDIC, meaning that
segmentation was reliant on interpretation at this point. All these variations impact the
flow dynamics in the CFD study.
Area variability directly interferes with the hydrodynamics of internal flows, but the
order of this influence also depends on other flow features. By looking at figures 5.7 and
5.8, it is evident that the sequences produce different WSS distributions, but that the main
features are in roughly the same area. Depending on the sequence studied, one may draw
different conclusions about the distribution of WSS in the artery of patient PRF1, as seen
in figure 5.7 a. TAWSS does not show how evenly distributed WSS was during the pulse
period, or any other dynamic characteristic of this quantity.
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Figure 5.5: Bland-Altmann plots for all phantom cases, showing differences in the measurement on the
y-axis, and mean value on the x-axis. (a) Agreement between MEDIC and ToF sequences, (b) Agreement
between high and low flow, (c) Agreement between high and low-curve.
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Figure 5.6: Overlapping segmentations of the MEDIC (blue) and ToF (red) images of patient AVF1.
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(a) WSS measurement
(b) OSI measurement
Figure 5.7: (a) WSS measurements and (b) OSI measurements for patient PRF1
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(a) WSS measurement
(b) OSI measurement
Figure 5.8: (a) WSS measurements and (b) OSI measurements for patient PRF2
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Vessel Patient EA ETAWSS EOSI
Artery PRF1 0.14 0.37 1.39
PRF2 0.09 0.25 0.73
PRF3 0.17 0.43 1.29
PRF4 0.22 0.44 1.23
Vein PRF1 0.17 0.25 0.84
PRF2 0.13 0.32 0.61
PRF3 0.28 0.37 0.65
PRF4 0.15 0.34 0.97
Table 5.2: Error analysis for patient data.
The OSI shows how strongly the direction of WSS forces changes during the pulse
cycle due to flow reversal or varying flow direction. In general, the regions of high OSI
do not correlate with regions of high TAWSS. In figure 5.9, it is possible to compare the
spatial distribution of OSI for both MEDIC and ToF sequences of patient PRF1. As the
only difference in those simulations is the vessel geometry, it is evident how sensitive
OSI is to variations in geometry. Intermittent flow separations happen at different posi-
tions, such as on the posterior and anterior vessel walls of the MEDIC and ToF sequences
respectively. In general, MEDIC showed more regions of high OSI than ToF, because
the geometry from higher-resolution MEDIC showed a more variable cross-sectional area
than that from ToF. Ef values for all patient cases, including area, WSS and OSI can be
seen in table 5.2 and figure 5.10.
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(c) ToF anterior.
xy
z
(b) MEDIC posterior.
x y
z
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Figure 5.9: Oscillatory shear index of the third pulse of patient PRF1.
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Figure 5.10: Error analysis for patient STL and CFD measurements
137
5.4 Discussion
In this study we have demonstrated that the choice of MRI sequence can lead to subtle
but important differences in segmented model geometry. The differences are of varying
magnitude throughout the length of the vessel, suggesting that local effects are causing the
observed differences in CFD results. The effect of this area variation caused significant
disagreement between the CFD results from the two MRI sequences.
The anastomosis of the AVF introduces challenges for MR imaging, and signal drop-
out was observed in all the anastomoses studied. Flow recirculation at the anastomosis
is reported in simulations of AVFs [49], and it is likely that this effect could be a major
cause of spin dephasing [175] resulting in signal loss at the anastomosis. Due to the
orientation of the swing site, flow is no longer confined along the z-axis of the B0 field,
effectively reducing the velocity of any incoming spins relative to the B0 field, which can
be another cause of signal loss. AVF flow has been demonstrated to be turbulent [145],
and this is the cause of the signature “thrill” of the AVF. Turbulent flow can undergo spin
dephasing causing MR signal heterogeneities, however, turbulent flow was observed in
the phantoms, and did not decrease the MRI signal. These problems may act together to
lower signal at the swing site and anastomosis, making this region particularly difficult to
segment and heavily reliant on operator interpretation, an under-reported aspect in most
CFD based studies of AVFs.
The signal distributions of the MEDIC and ToF sequences were analyzed using a se-
ries of phantoms, and no difference was observed in the signal intensity profiles from
the vessels. However, the ToF sequence was intrinsically more noisy, and the MEDIC
produced a higher signal from stationary water used to prime the scanner. An analogous
geometry to the curved swing-site segment of the AVF was created using two curved phan-
toms. Next, the effect of an off-axis flow on signal intensity measurements for the two
different curves was assessed. This led to the observation that for the MEDIC sequence,
the signal intensity was inversely proportional to the rate of change of the flow-direction
(as assessed by Γ′), which may be a reason for the observed signal dropout in the patient
images. Signal loss in the curved phantom was not apparent on the ToF images, but both
sequences exhibited signal loss on the patient images at the swing-site, suggesting that
local flow effects at the anastomosis may have more effect than flow-direction effects as
represented by Γ (Eq. 5.4).
The area disagreement EA between the straight phantoms increased as the tube di-
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ameter was decreased, which would be expected as the size of the phantom reduces and
approaches the resolution of the scanner. The error was also increased in the curved
phantoms as compared with the straight phantoms of the same diameter. Increased dis-
agreement was observed when the flow velocity was changed, which is likely due to the
use of “out-of-the-box” sequences. A main benefit of “out-of-the-box” sequences is the
ability to image vessels with both high and low-velocity flows in one sitting. However,
optimization of the sequences could be performed to find the parameters which give the
truest geometric depiction for each flow velocity, or to identify the parameters which re-
duce the error between the velocities.
These geometric errors propagate into larger errors for parameters derived from CFD.
The error metric EWSS was larger than EA for every patient vessel studied (table 5.2
and Fig. 5.10). Wall shear stress and cross-sectional area are inversely related through a
straight vessel, as given by the Darcy-Weisbach equation
τw =
fD
8
ρ
(
Q
A
)2
, (5.7)
where fD is an empirical friction factor, ρ is fluid density, Q is flow rate, and A is area. In
the laminar regime, the relation of WSS and area is weaker (τw ∝ A−1.5), because the fric-
tion factor is inversely proportional to the Reynolds number (Re), fD = 64/Re. However,
in the turbulent regime, the friction factor does not scale with Re, but it rather depends
more on the roughness of the vessel, which leads to a second-order inverse relationship
between WSS and area (τw ∝ A−2). Hence, it is important that accurate measurements
of vessel area are obtained for accurate estimation of WSS. As OSI is derived from WSS,
and depends on more non-linear effects, such as flow separations, EOSI was significantly
larger than EA and EWSS for all cases studied.
This study has a number of limitations. One user segmented the geometries from all
MR image sets, so it was not possible to assess variability between operators. This is well
covered in the literature and was not the purpose of our study. We did not compare our
results to an experimental model, such as in the FDA-sponsored study [167].
No comparison was made with any black-blood sequences or other modalities such as
CT, which are also used in to create 3D models for CFD studies of AVFs. Black-blood
MRI has been shown to yield good results when measuring vessel parameters for intracra-
nial vessels [10]. Similarly to this work, authors signify that sequence parameters affect
wall measurements and sharpness of the vessel wall boarders, which require optimization
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prior to commencing the study. Black blood MRA should in theory help with measure-
ments of rapidly flowing or turbulent blood, which may yield low signal due to loss of
spins phase-coherence and in-flow effects. Use of black-blood techniques in lumen mea-
surements of AVFs and CFD modeling of wall shear stress has been demonstrated [63].
Another emerging method not considered in this study is 4D flow MRI. In addition to
morphological information, the technique has been shown to non-invasively characterize
physiological properties, such as velocity, flow volume, wall shear stress, pressure gra-
dients, streamlines and flow path lines in cerebral arteriovenous malformations [31]. 4D
flow MRI has been shown to currently underestimate WSS values in intracranial arteries,
but with good estimate of WSS distribution when compared to CFD methods [169].
In conclusion, we have demonstrated that different MRI sequences do not give re-
producible results when considering CFD studies of AVFs. The results from this study
should be taken into consideration when planning patient specific CFD studies. Compar-
isons with known results from experiment should be performed to fully understand the
effect of changing MRI sequence for these studies, and to determine which sequences
provide geometries closest to the ground-truth.
140
Chapter 6
Conclusions, impact, and future work
6.1 Conclusions
The main purpose of this thesis was to identify additional risk-factors for AVF failure
in order to aid in clinical decision making, aid in patient counseling towards the risk of
failure, and ultimately increase long-term patency. In attempt to identify these factors,
blood-borne biomarkers, new ultrasound and MRI methods were studied.
Chapter 2 aimed to determine if pre-operative serological markers, and known risk-
factors were predicative of AVF outcome in a single centre, retrospective study, as well as
provide up to date patency rates for the local cohort. Pre-operative levels of ferritin and
phosphate were identified as independent risk-factors for AVF failure in a small retrospec-
tive study. Known risk-factors such as age and gender were not significantly related to the
outcome in this study. Diabetes was not identified as a marker during logistic regression
modeling, but its inclusion as a variable in the KNN model with ferritin and phosphate
categorised over 70 % of test patients correctly. Primary AVF failure in this group was
around 30 % at 1-year, in line with literature values. A very high primary assisted patency
of over 90 % was observed, demonstrating the benefits of post-operative US surveillance.
Chapter 3 aimed to determine if pre-operative measurements of arterial elasticity and
strain could act as novel risk-factors for AVF failure. Neither SWE nor VVI measure-
ments were predicative of the clinical success or failure of the AVF, but both were shown
to have potential in peripheral vascular sonography. Alongside this, a marked decrease in
arterial stiffness of the brachial artery was observed following AVF creation.
Chapter 4 aimed to determine if 3T MRI was a feasible imaging platform for these
patients, and described a small pilot study involving MEDIC MR imaging of AVFs in
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order to test the technique in the central vessels in the future. MEDIC showed good
agreement with US, an ability to profile the cross-sectional area of the vessels at a high
resolution, and lumen edge depiction at the anastomosis, indicating that it may find benefit
as part of a patient’s workup prior to AVF creation.
Finally, chapter 5 used these same MR images to demonstrate a degree of variability
in CFD simulations, indicating that one cannot freely change MRI sequence and expect
identical results in these simulations.
6.2 Impact
The inflammatory markers CRP and albumin have been studied previously, with mixed
results. This work found no relation between CRP, albumin, and the outcome of the AVF,
adding to the negative result literature. The relationship observed between ferritin and
phosphate on AVF outcome has not been observed previously. However, one study does
not provide a guarantee it will be observed in other cohorts awaiting AVF creation, but
should be followed up.
The lack of establishing additional risk-factors from US, using novel markers of ar-
terial stiffness, reflects the difficulty previous researchers have experienced in this field.
Arterial stiffness has previously demonstrated no relationship to AVF outcome, although
only a handful of studies have searched for such a correlation. This work adds to the body
of negative results. However, this work does demonstrate the value of the SWE technique
in vascular ultrasound, and adds to the literature supporting its use, particularly in assess-
ments of arterial stiffness. The observation that larger arteries result in larger arterial AVF
segments should come as no surprise, and supports previous research that larger vessels
should be used for AVF creation where possible.
The demonstrated feasibility of NCE-MRI (re)opens an additional avenue for the
study of AVFs. It is possible that the additional spatial resolution and anatomical data
may prove useful in clinical planning for certain types of patients, or may prove useful in
detecting possible high-risk areas for stenosis development. However, the specific patient
groups who may benefit from this imaging are still to be determined.
6.3 Future work
This thesis leaves specific opportunities for further study:
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Chapter 2 leaves the possibility of further study regarding serological markers. Further
studies should investigate the effect of ferritin and phosphate, determining values to act
as cut-off for increased risk, ideally in a prospective study. Following this, work could be
performed to determine the mechanisms by which they can cause AVF failure.
Chapter 3 leaves possibilities for following-up the demonstrated US methods. The de-
creased SWV in the brachial artery is an interesting observation, and histological study to
determine what is its cause could be performed. It would also be interesting to determine
the effect of varying blood-pressure on SWV measurements for similarly sized arteries.
Further trials could be performed using SWE, now that is has been demonstrated to be
a robust method. Larger cohort studies, with longer followup of patients awaiting AVF
creation could be undertaken to determine if SWE can act as a risk-factor for AVF failure.
Further work could be performed to determine the limits of the VVI package, as previ-
ous research indicates that assessment of the carotid seems feasible, but the brachial artery
introduced difficulties. The observation of irregular velocity profiles has been observed
in previous patient cohorts. However, in this study irregular profiles were observed in
healthy volunteers. Further research should assess if this phenomenon is merely a probe
movement artefact, or a genuine finding.
Chapter 4 has demonstrated the feasibility of 3T MRI in this cohort. Now that the
MEDIC MRI sequence has shown good agreement with US, further clinical study could
be undertaken to determine it’s ability to detect or predict stenosis. An extension to the
central vessels should be considered high priority, in order to obtain a non-invasive imag-
ing modality for use in this patient cohort. Perhaps the use of non-contrast enhanced
MRI sequences can restart the MRI based study of AVFs, which has slowed since the
association of Gd based contrast with nephrogenic systemic fibrosis.
Previous work in CFD has demonstrated that imaging modalities are not wholly inter-
changeable, and the work in chapter 6 demonstrates that MRI sequences are not wholly
interchangeable. Further work is required to determine which MRI sequence provides ge-
ometries closes to the ground truth, and that provide results that agree with experiments.
Following this, the magnitude of error compared to experiment could be determined, al-
lowing selection of the best sequence for imaging.
In this typically aged group with a high-level of co-morbidities, a multi-factorial
method may be more beneficial. Further research incorporating large cohorts, long fol-
lowup, and results from imaging, serological biomarkers, and existing comorbidities/risk-
factors would be interesting. Such an outlook may be the eventual method which identifies
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a reliable risk-factor, eventually allowing primary patency rates to increase.
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[28] F. Candan, G. Yildiz, and M. Kayataş. Role of the VEGF 936 gene polymorphism
and VEGF-A levels in the late-term arteriovenous fistula thrombosis in patients
undergoing hemodialysis. Int. Urol. Nephrol., 46(9):1815–1823, sep 2014.
[29] G. T. Carroll, T. M. McGloughlin, P. E. Burke, M. Egan, F. Wallis, and M. T.
Walsh. Wall Shear Stresses Remain Elevated in Mature Arteriovenous Fistulas: A
Case Study. J. Biomech. Eng., 133(2):021003, feb 2011.
[30] M. Cecelja and P. Chowienczyk. Role of arterial stiffness in cardiovascular disease.
JRSM Cardiovasc. Dis., 1(4):1–10, jul 2012.
[31] W. Chang, M. W. Loecher, Y. Wu, D. B. Niemann, B. Ciske, B. Aagaard-Kienitz,
S. Kecskemeti, K. M. Johnson, O. Wieben, C. Mistretta, and P. Turski. Hemody-
namic changes in patients with arteriovenous malformations assessed using high-
resolution 3D radial phase-contrast MR angiography. AJNR. Am. J. Neuroradiol.,
33:1565–72, 2012.
[32] T.-C. Chen, C.-Y. Wang, C.-Y. Hsu, C.-H. Wu, C.-C. Kuo, K.-C. Wang, C.-C.
Yang, M.-T. Wu, F.-R. Chuang, and C.-T. Lee. Free p -Cresol Sulfate Is Associated
with Survival and Function of Vascular Access in Chronic Hemodialysis Patients.
Kidney Blood Press Res, 35:583–588, 2012.
[33] K. S. Cheng, C. R. Baker, G. Hamilton, A. P. Hoeks, and A. M. Seifalian. Arte-
rial elastic properties and cardiovascular risk/event. Eur. J. Vasc. Endovasc. Surg.,
24(5):383–397, 2002.
[34] S.-C. Chien, C.-Y. Chen, C.-F. Lin, and H.-I. Yeh. Critical appraisal of the role of
serum albumin in cardiovascular disease. Biomark. Res., 5(1):31, 2017.
148
[35] J. A. Chirinos. Arterial stiffness: Basic concepts and measurement techniques. J.
Cardiovasc. Transl. Res., 2012.
[36] I. J. Cho, C. Y. Shim, W. I. Yang, S. A. Kim, H. J. Chang, Y. Jang, N. Chung,
and J. W. Ha. Assessment of Mechanical Properties of Common Carotid Artery
in Takayasu’s Arteritis Using Velocity Vector Imaging. Circ. J., 74(7):1465–1470,
2010.
[37] G. Choi, C. P. Cheng, N. M. Wilson, and C. A. Taylor. Methods for quantifying
three-dimensional deformation of arteries due to pulsatile and nonpulsatile forces:
Implications for the design of stents and stent grafts. Annals of Biomedical Engi-
neering, 37(1):14–33, 2009.
[38] C.-Y. Y. Chou, H.-L. L. Kuo, Y.-F. F. Yung, Y.-L. L. Liu, and C.-C. C. Huang.
C-reactive protein predicts vascular access thrombosis in hemodialysis patients.
Blood Purif., 24(4):342–346, aug 2006.
[39] J.-M. Corpataux, E. Haesler, P. Silacci, H. B. Ris, and D. Hayoz. Low-pressure
environment and remodelling of the forearm vein in Brescia-Cimino haemodialysis
access. Nephrol. Dial. Transplant, 17(6):1057–62, jun 2002.
[40] M. C. Corretti, T. J. Anderson, E. J. Benjamin, D. Celermajer, F. Charbonneau,
M. A. Creager, J. Deanfield, H. Drexler, M. Gerhard-Herman, D. Herrington,
P. Vallance, J. Vita, and R. Vogel. Guidelines for the ultrasound assessment of
endothelial-dependent flow-mediated vasodilation of the brachial artery. J. Am.
Coll. Cardiol., 39(2):257–265, jan 2002.
[41] M. Couade, M. Pernot, C. Prada, E. Messas, J. Emmerich, P. Bruneval, A. Criton,
M. Fink, and M. Tanter. Quantitative Assessment of Arterial Wall Biomechanical
Properties Using Shear Wave Imaging. Ultrasound Med. Biol., 36(10):1662–1676,
2010.
[42] V. CT, R. Klein, M. SE, and K. BK. The risk of cardiovascular disease mortality
associated with microalbuminuria and gross proteinuria in persons with older-onset
diabetes mellitus. Arch. Intern. Med., 160(8):1093–1100, apr 2000.
[43] L. A. Dageforde, K. A. Harms, I. D. Feurer, and D. Shaffer. Increased minimum
vein diameter on preoperative mapping with duplex ultrasound is associated with
149
arteriovenous fistula maturation and secondary patency. J. Vasc. Surg., 61(1):170–
176, jan 2015.
[44] R. Dammers, J. H. M. Tordoir, J. P. Kooman, R. J. T. J. Welten, J. M. M. Hameleers,
P. J. E. H. M. Kitslaar, and A. P. G. Hoeks. The effect of flow changes on the
arterial system proximal to an arteriovenous fistula for hemodialysis. Ultrasound
Med. Biol., 31(10):1327–1333, oct 2005.
[45] L. M. Dember, P. B. Imrey, M.-A. Duess, N. M. Hamburg, B. Larive, M. Radeva,
J. Himmelfarb, L. W. Kraiss, J. W. Kusek, P. Roy-Chaudhury, C. M. Terry, M. A.
Vazquez, W. Vongpatanasin, G. J. Beck, and J. A. Vita. Vascular Function at Base-
line in the Hemodialysis Fistula Maturation Study. J Am Heart Assoc, 5(7):e00322,
2016.
[46] B. Dixon. Why don’t fistulas mature? Kidney Int., 70(8):1413–1422, oct 2006.
[47] C. Doelman, L. E. Duijm, Y. S. Liem, C. L. Froger, A. V. Tielbeek, A. B. Donkers-
van Rossum, P. W. Cuypers, P. Douwes-Draaijer, J. Buth, and H. C. van den Bosch.
Stenosis detection in failing hemodialysis access fistulas and grafts: Comparison
of color Doppler ultrasonography, contrast-enhanced magnetic resonance angiog-
raphy, and digital subtraction angiography. J. Vasc. Surg., 42(4):739–746, oct 2005.
[48] M. El-Abbadi and C. M. Giachelli. Arteriosclerosis, calcium phosphate deposi-
tion and cardiovascular disease in uremia: current concepts at the bench. Current
Opinion in Nephrology and Hypertension, 14(6), 2005.
[49] B. Ene-Iordache, L. Cattaneo, G. Dubini, and A. Remuzzi. Effect of anastomosis
angle on the localization of disturbed flow in ’side-to-end’ fistulae for haemodialy-
sis access. Nephrol. Dial. Transplant., 28(4):997–1005, 2013.
[50] B. Ene-Iordache and A. Remuzzi. Disturbed flow in radial-cephalic arteriovenous
fistulae for haemodialysis: Low and oscillating shear stress locates the sites of
stenosis. Nephrol. Dial. Transplant., 27(1):358–368, 2012.
[51] A. Farber, P. B. Imrey, T. S. Huber, J. M. Kaufman, L. W. Kraiss, B. Larive, L. Li,
and H. I. Feldman. Multiple preoperative and intraoperative factors predict early
fistula thrombosis in the Hemodialysis Fistula Maturation Study. J. Vasc. Surg.,
63(1):163–170.e6, 2016.
150
[52] G. Ferraioli, C. Tinelli, B. Dal Bello, M. Zicchetti, G. Filice, and C. Filice. Ac-
curacy of real-time shear wave elastography for assessing liver fibrosis in chronic
hepatitis C: A pilot study. Hepatology, 56(6):2125–2133, 2012.
[53] C. S. Fox, K. Matsushita, M. Woodward, H. J. Bilo, J. Chalmers, H. J. L. Heer-
spink, B. J. Lee, R. M. Perkins, P. Rossing, T. Sairenchi, M. Tonelli, J. A. Vassalotti,
K. Yamagishi, J. Coresh, P. E. de Jong, C.-P. Wen, and R. G. Nelson. Associations
of kidney disease measures with mortality and end-stage renal disease in individu-
als with and without diabetes: a meta-analysis. Lancet, 380(9854):1662–1673, nov
2012.
[54] A.-S. Garnier and M. Briet. Arterial Stiffness and Chronic Kidney Disease. Pulse,
3(3-4):229–241, mar 2016.
[55] G. S. Georgiadis, D. G. Charalampidis, C. Argyriou, E. I. Georgakarakos, and
M. K. Lazarides. The Necessity for Routine Pre-operative Ultrasound Mapping
Before Arteriovenous Fistula Creation: A Meta-analysis. Eur. J. Vasc. Endovasc.
Surg., 49(5):600–5, may 2015.
[56] M. Ginsburg, J. M. Lorenz, S. P. Zivin, S. Zangan, and D. Martinez. A practical
review of the use of stents for the maintenance of hemodialysis access. Seminars
in interventional radiology, 32(2):217–224, 06 2015.
[57] A. J. Gonzalez, K. M. Casey, B. J. Drinkwine, and J. S. Weiss. Series of Noncon-
trast Time-of-Flight Magnetic Resonance Angiographies to Identify Problems with
Arteriovenous Fistula Maturation. Ann. Vasc. Surg., 30:93–9, jan 2016.
[58] C. M. Gullion, D. S. Keith, G. A. Nichols, and D. H. Smith. Impact of Comor-
bidities on Mortality in Managed Care Patients With CKD. Am. J. Kidney Dis.,
48(2):212–220, 2006.
[59] N. J. Haddad, S. V. Cleef, and A. K. Agarwal. Central Venous Catheters in Dialysis:
The Good, the Bad and the Ugly. Open Urol. Nephrol. J., 1(5):12–18, 2012.
[60] M. Hammes. Importance of the Endothelium in Arteriovenous Fistula Outcomes.
Am. J. Nephrol., 60637:426–427, 2016.
[61] A. Han, S.-K. Min, M.-S. Kim, K. W. Joo, J. Kim, J. Ha, J. Lee, and S.-i. Min.
A Prospective, Randomized Trial of Routine Duplex Ultrasound Surveillance on
151
Arteriovenous Fistula Maturation. Clin. J. Am. Soc. Nephrol., 11(10):1817–1824,
oct 2016.
[62] S. Harada, M. Yamakido, M. Yalniz, Ç. Özbaşli, J. L. Teruel, G. F. Juarez,
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